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ABSTRACT 
 
Pharmacological Regulation of c-myc Gene Expression in Human Breast Cancer 
Cells 
 
Zaroui K. Melkoumian 
 
Previous studies demonstrated that quinidine causes G1/G0 cell cycle arrest and 
inhibition of proliferation in MCF-7 human breast cancer cell line (Woodfork, K. et al, 
1995). The goal of studies reported here was to understand the molecular mechanisms of 
c-myc gene regulation by quinidine. c-myc is one of the most common oncogene 
aberrations in breast cancers (Deming, S.L. et al, 2000). c-myc functions include 
regulation of cell cycle, proliferation, differentiation, and apoptosis. The results of these 
studies demonstrated that quinidine causes rapid (within 1 hour) suppression of Myc 
protein and mRNA levels that precedes the quinidine-induced G1 cell cycle arrest point 
(D point) in MCF-7 cells. Additionally, the activity of c-myc promoter was suppressed by 
quinidine over the same range of concentrations that suppress levels of c-myc mRNA and 
protein, suggesting that changes in Myc protein and mRNA levels by quinidine may be 
attributed to its effect on c-myc promoter. A 168 bp region of c-myc promoter (-100 to 
+68 in respect to P1) was identified as a quinidine responsive region (QRR). Suppression 
of Myc by quinidine was consistent with inhibition of growth and induction of more 
differentiated phenotype in four different breast tumor cell lines. In contrast, quinidine 
had minimal effect on Myc levels or proliferation in normal mammary epithelial cell 
lines. Furthermore, MCF-7 cells treated with c-myc antisense oligonucleotides exhibited 
cytoplasmic lipid droplets, similarly to the quinidine-treated cells, suggesting that 
suppression of Myc may play a causative role in the induction of more differentiated 
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1. Breast Cancer 
1.1.  Current methods of breast cancer therapy 
Worldwide, breast cancer remains the most common malignancy affecting women, 
accounting for 18 % of all female cancers (McPherson, K. et al, 2000). In the United States 
each year more than 180,000 women are diagnosed with breast cancer and 44,000 will die 
from this disease (NIH, 2000) making it the second leading cause of cancer death among the 
females after lung cancer. Risk factors for the development of breast cancer include older 
age, immediate family history of breast cancer at a young age or bilateral breast cancer, early 
menarche, late menopause, nulliparity, use of hormone replacement therapy, exposure to 
ionizing radiation at a young age, lifestyle, and past history of atypical hyperplasia, in situ or 
invasive carcinoma (McPherson, K., et al, 2000).  
Current methods of breast cancer therapy include surgery, radiation, cytotoxic and 
hormonal chemotherapy, and preventive chemotherapy. The clinical management of breast 
cancer patients is guided by the number of parameters, including tumor size, histological type 
or grade, the presence of steroid receptors, involvement of the axillary lymph nodes, and 
presence of metastasis (NIH, 2000). Carcinoma in situ is a preinvasive lesion within breast 
without penetration of the basement membrane and the potential for metastasis. Intralobular 
and intraductal carcinomas in situ are treated with the local surgical excision and wide local 
excision following by irradiation, respectively (Harris, J.R. et al, 1992). Primary breast 
cancers are treated with modified radical mastectomy or partial mastectomy following by 
external beam irradiation (Fisher, B. et al, 1989). Axillary lymph node dissection during the 
surgery is necessary to determine the adjuvant therapy of choice, since axillary nodal 
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involvement is predictive of relapse in operable breast cancer. Because adjuvant 
polychemotherapy (≥ 2 agents) has been shown to substantially improve the long-term, 
relapse-free, and overall survival, it should be recommended to the majority of women with 
localized breast cancer regardless of nodal, menopausal, or hormone receptor status (NIH, 
2000). The currently recommended adjuvant therapy includes tamoxifen treatment for five 
years among women aged over 50 years and standard oral CMF (Cyclophosphamide, 
Methotrexate, 5-Fluorouracil) for six months or ovarian ablation in women younger than 50 
years (NIH, 2000; Fisher, B. et al, 1990; Wood, W.C.  et al, 1994). The benefit from 
tamoxifen therapy is nearly doubled for patients with Estrogen Receptor (ER) rich tumors 
compared to ER poor ones.  
Virtually all of the deaths in the United States due to breast cancer are associated with 
progressive metastatic breast cancer. Unfortunately, there is no cure for this stage of breast 
cancer, although the length and quality of patients’ lives with metastatic cancer varies 
greatly. Clinical studies showed that about one third of patients with metastatic breast cancer 
will respond to endocrine therapy (Glauber, J.G. and Kiang, D.T., 1992). Endocrine agents 
are best used as initial therapy in older patients with ER-positive tumors. First-line endocrine 
therapy for postmenopausal patients generally consists of tamoxifen, followed by a progestin 
(Megestrol acetate), high dose estrogen, an aromatase inhibitor (Anastrozole), or androgen 
(Fluoxymesterone) when tumor progression occurs. For premenopausal patients, 
oophorectomy or tamoxifen treatment may be considered first, followed by progestin or 
androgen treatment in the event of progression (Glauber, J.G. and Kiang, D.T., 1992). The 
median duration of response to any of these endocrine therapies is between one and two 
years. Although chemohormonal treatment may lead to higher response rates compared to 
 3 
hormonal therapy alone, a survival benefit has not been demonstrated. About two-thirds of 
all patients with metastatic breast cancer will have a response to some form of cytotoxic 
chemotherapy. The median duration of response is six to twelve months (Henderson, I.C. and 
Harris, J.R., 1991). The most widely used combinations in the treatment of metastatic breast 
cancer are CAF (Cyclophosphamide, Adriamycin, 5-Fluorouracil) and CMF 
(Cyclophosphamide, Methotrexate, 5-Fluorouracil) (Abramowicz, M., 2000). Second-line 
therapy for refractory patients results in lower response rate and duration of response 
compared to those for front-line therapy. Paclitaxel (Taxol) is recommended for second-line 
therapy of metastatic breast cancer (Seidman, A.D., 1994). Other second-line agents include 
mitomycin C and vinblastine, yielding response rates of 25 to 30% (Henderson, I.C. and 
Harris, J.R., 1991).  
The major limitation associated with the use of cytotoxic chemotherapeutic agents is their 
lack of selectivity for tumor cells and associated with it toxicity in normal tissues. In general, 
anticancer drugs affect rapidly dividing cells. These include tumor cells, hematopoetic cells, 
cells that line the digestive tract, and hair follicle cells. Accordingly, the most common side 
effects of cancer chemotherapy are immunosuppression, GI disturbances, and alopecia (hair 
loss). There are also other toxicities associated with some anticancer drugs. For example, 
high doses of methotrexate can cause acute renal failure and neurotoxicity. Doxorubicin at 
cumulative doses exceeding 450 mg/m2 causes significant cardiotoxicity (Von Hoff D.D. et 
al, 1979). Also mutagenic potential of some chemotherapeutic agents can cause development 
of secondary tumors, such as leukemia. There are several side effects associated with 
endocrine therapy as well. Recent study by Fisher, B. and coworkers (Fisher, B. et al, 1998) 
showed that tamoxifen increases the women's risk for three rare but life-threatening health 
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problems: endometrial cancer (cancer of the lining of the uterus), pulmonary embolism 
(blood clot in the lung), and deep vein thrombosis (blood clots in major veins). Another 
important problem in cancer therapy is a development of resistance to antineoplastic drugs. 
Were it not for drug resistance, control and cure of most cancers would be possible. 
Some of the most exciting developments in cancer research were the discovery of 
oncogenes and tumor suppressor genes, as well as the better understanding of the internal and 
external stimuli that result in malignant transformation, tumor progression, invasion, and 
metastasis. The advances in our understanding of the basic biology of breast carcinoma 
contributed to the development of novel approaches to cancer treatment to supplement 
traditional chemotherapy. One such example is a development of monoclonal antibody, 
trastuzumab (Herceptin) to epidermal growth factor receptor HER-2/neu. This antibody binds 
with great affinity to the extracellular domain of HER-2 and inhibits the transmission of 
growth stimulatory signal. In clinical trials Herceptin as a single agent has been shown to 
produce antitumor responses in 15-20 % of patients with metastatic breast carcinoma 
(Baselga, J. et al, 1998; Cobleigh, M.A. et al, 1998). Another area of intensive research is the 
development of Selective Estrogen Receptor Modulators (SERM). Based on our growing 
knowledge about estrogen receptor subtypes, their distribution and functions in different 
tissues, researchers are searching for compounds, that would function as a potent anti-
estrogens in the breast and uterus to prevent estrogen-driven cell proliferation and, at the 
same time, have strong estrogenic effects in bone, the cardiovascular system, and the central 
nervous system, where the hormones have beneficial effects. To date, the only three SERM 
available on the market are tamoxifen (Nolvadex), raloxifene (Evistar), and toremifene, 
although there are more second and third generation SERM showing promising results in 
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preclinical data (McNeil, C., 1998, Williams, G.M., 1998; Labrie, F. et al, 1999). Selective 
targeting of deregulated oncogenes in cancer cells with antisense oligonucleotides or delivery 
of disrupted tumor suppressor genes using viral vectors are other advancing areas in cancer 
research. 
Due to the tremendous progress in breast cancer research, for the first time the annual 
mortality rates are decreasing in the United States (NIH, 2000). There is still more to learn 
about breast cancer genetics, breast cancer susceptibility genes, such as BRCA1 and BRCA2, 
molecular mechanisms regulating mitogenic stimulation, and malignant transformation in 
breast cancer cells. This knowledge may reveal new pharmacological targets for the 
development of better therapeutic approaches to treat breast cancer.  
The next section of the introduction provides a general overview of basic cell cycle 
regulatory processes, as well as more detailed discussion of G1 to S phase transition in MCF-
7 human breast cancer cell line. The purpose of these background materials is to facilitate 
understanding of the subsequent sections of the introduction, disusing functional role of c-
myc gene in cell cycle regulation. 
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2. Cell Cycle 
2.1.  General overview 
The cell cycle is a sequence of highly ordered and controlled processes that results in a 
duplication of a cell. The cell cycle consists of 4 distinct phases: G1, S, G2 and M. DNA 
replication and cell division (cytokinesis) occur during the S and M phases, respectively. Gap 
phases (G1 and G2) precede S and M phases and are responsible for the synthesis of essential 
proteins for DNA replication and mitosis. Certain conditions, for example starvation, 
differentiation cause cells to exit from the cell cycle into a non-proliferative state, called G0 
phase. Some non-dividing cells, such as skeletal muscle fibers, are unable to re-enter the cell 
cycle. Other, such as lymphocytes, hepatocytes and fibroblasts are usually in G0 but can be 
activated by external agents (mitogens) to enter cell cycle. Each phase of the cell cycle is 
regulated by three families of key cell cycle regulatory proteins: cyclins, Cyclin Dependent 
Kinases (CDKs), and Cyclin-dependent Kinase Inhibitors (CKIs). In response to mitogenic 
stimuli, such as growth factors, there is a transient increase in levels of cell cycle phase-
specific cyclins. Each cyclin binds to the corresponding CDK and activates its catalytic 
subunit. Activated CDK then phosphorylates another important cell cycle regulator, the 
retinoblastoma protein, pRb. A schematic diagram of the temporal relationship between 
different cyclin/CDK complexes and cell cycle phases are shown in Figure 1. Cyclin D1 is 
expressed throughout G1 phase but its peak occurs during mid G1. The main function of 
cyclin D1 is to activate CDK4/6 catalytic subunits to induce initial phosphorylation of pRb. 
Cyclins E and A begin to rise later in G1. They are responsible for activation of CDK2 to 
maintain pRb in its hyperphosphorylated state during the late G1 and ensure G1 to S 






Figure 1.  Temporal relationship between expression of Cyclin-Cdk complexes (dashed 
lines) and different phases of cell cycle (solid lines). 
 
R – late G1 restriction site 
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transcription regulators, collectively called the E2Fs, which can transactivate genes whose 
products are essential for S phase entry. Some of these genes are dihydrofolate reductase, 
thymidylate synthase, DNA polymerase α, and DNA polymerase δ subunit PCNA. 
In the complex with pRb, E2Fs are unable to perform their function as transcription 
factors. Phosphorylation of pRb by CDKs removes its inhibitory capacity, causing release of 
E2Fs, which then transactivate the expression of genes needed for entry into S phase. 
Activation of E2F-1 also leads to transcriptional activation of cyclin E and A, reinforcing the 
initial activation of E2F. Figure 2 summarizes these events. Extracellular stimuli initiate 
progression of cells from G1 to S; other events regulate progression of cells from S phase 
into G2 and from G2 into M phase. These transitions are controlled by internal signals that 
are triggered by the completion of biosynthetic processes unique to S and G2 phases, 
respectively. They are insensitive to external conditions (Murray, A.W. and Kirschner, 
M.W., 1989).  The point in G1 phase beyond which a cell is no longer dependent on the 
presence of extracellular factors and is committed to complete cell cycle is called the G1 
"restriction point" or “R point" (Pardee, A.A, 1974). When fibroblasts are arrested in R, for 
example by withdrawal of growth factors for a long period of time, they will enter quiescence 
state or G0 (Campisi, J. and Pardee, A.B., 1984).  
In addition to the positive regulation by cyclins, CDK activity is negatively regulated by 
another important family of cell cycle regulatory proteins: Cyclin-dependent Kinase 
Inhibitors, CKIs. These inhibitors can be up-regulated when required, thus blocking the 
activation of CDKs by cyclins. The known CKIs are grouped into two gene families, Ink4 
and Cip/Kip, according to structural similarities. The Cip/Kip family consists of p21, p27, 
and p57. p21 is also known as Wild-type p53 Activated  Fragment 1 (WAF1) or CDK2 
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Interacting Protein 1 (CIP1). p27 and p57 are known as Kinase Inhibitory Protein 1 (Kip1) 
and 2 (Kip2), respectively. These inhibitors tend to have wide ranging roles and can 
potentially inhibit a number of different CDKs. The Ink4 (for inhibitor of CDK4) family is 
far more specific and consists of p15 INK4b, p16 INK4a, p18 INK4c, p19 INK4d (Anxo Vidal and 
Andrew Koff, 2000). Until recently it was thought that Ink4 family members were only 
involved in inhibiting CDK4. However, a second INK4A gene product has been identified 
recently, p19 ARF, which binds to and inactivates the p53 regulatory protein, MDM2, thus 
allowing increased p53 stability and subsequent cell cycle arrest (Pomerantz, J. et al, 1998). 
Abnormalities in many positive and negative modulators of the cell cycle are frequent in 
most cancer types. As a result, cancer cells possess increased and deregulated proliferative 
activity. In normal cells, cell cycle regulators are subject to strict control and their activities 
fluctuate according to external stimuli (growth factors), whereas in tumor cells a variable 













Figure 2. Schematic representation of pRb phosphorylation by cyclin/CDK complexes 
and E2F release during G1 to S progression.  
 
Members of the Ink and Cip/Kip families of cyclin-dependent kinase inhibitors (CKI) are 
shown in blue and green, respectively. 
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2.2.  G1 to S phase progression in MCF-7 human breast cancer cells 
The goal of these studies was to understand the molecular mechanisms of c-myc gene 
regulation by quinidine in human breast cancer cells. A brief description of the cell cycle in 
MCF-7 cells, with the emphasis on G1-S progression in this cell line is provided. Most of the 
data described in this section were obtained in Dr. Strobl's and Dr. Wonderlin's laboratories.  
A schematic diagram of G1 to S progression, the temporal relationship between two 
different G1 control points, and the levels of cell cycle regulatory proteins in MCF-7 cells is 
shown in Figure 3. The doubling time of MCF-7 cells was calculated by counting cell 
numbers in a cell population engaged in exponential growth. The doubling time was 52 
hours. The fraction of cells in G1, S , and G2+M phase was calculated using flow cytometry 
analysis and immunohistochemical staining of Ki-67 antigen (Shiyi Wang, et al, 1998). Flow 
cytometry allows one to calculate the percentage of cells in G1+G0, S, and G2+M phases, 
based on their DNA content, but it does not discriminate between cells in G1 and G0 phase. 
Ki-67 is the nuclear antigen, that is present only in cycling cells (G1, S, G2, and M phases) 
and is absent in G0 cells, allowing for distinction of cells in G0. Based on the cell doubling 
time and cell fraction in each cell cycle phase, the duration of G1, S, and G2+M was 







Figure 3. Temporal relationship between different regulatory events during the G1 to S 
phase transition in MCF-7 human breast cancer cells.  
 
0he duration of the G1 and S phases is shown in black and red solid lines, respectively. The 
time required for the cells to reach mid-S phase, after washout of lovastatin (21hr) or 
quinidine (27 hr), or after release of cells from a high cell density condition (30 hr) is shown 
with black brackets. The peak of Myc protein occurs 1.5 hr after release from the high 
density state as shown by the arrow. The phosphorylation status of pRb is shown in black 
(hypophosphorylation) and red (hyperphosphorylation), respectively. D-quinidine arrest 
point, L - lovastatin arrest point, G0 - G0 state. Based upon data published in Woodfork, 
K.A. et al, 1995; Strobl, J.S. et al, 1995; Wang, S. et al, 1998; Zhou, Q. et al, 2000; Wang, S. 
thesis, 1996; Melkoumian, Z. and Strobl, J., 1999. 
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 Over the past several years, our laboratory has tried to define the mechanism, by which 
the potassium channel blocking agent, quinidine, inhibits proliferation in human breast 
cancer cells. Studies by Woodfork, K. showed that quinidine caused arrest of MCF-7 cells in 
G1/G0 phase of the cell cycle (Woodfork, K.A. et al, 1995; Strobl, J.S. et al, 1995). This 
quinidine arrest point was called the depolarization control point or D point. The important 
role of membrane potential and its changes by quinidine in regulation of cell progression 
through the D point are discussed later in the introduction.  Shiyi Wang estimated the 
location of the D point by comparing the time course of synchronous S phase re-entry after 
drug washout form MCF-7 cells arrested in G1/G0 phase by quinidine or known G1 arresting 
drug, lovastatin (Shiyi Wang et al, 1998). Cells arrested by lovastatin and quinidine peaked 
in mid S phase 21 and 27 hours, respectively after the drug washout. Accordingly, the D-
point was designated prior to the lovastatin arrest point and 19.5 hours preceding the G1/S 
border. In general, MCF-7 cells growing in tissue culture reach the high density/confluency 
state around 5-6 days after passaging.  At this state the cell monolayer covers about 90% of 
the growth surface and most of the cells are in G1/G0 (Wang, S., et al, 1998). The flow 
cytometry analysis showed that MCF-7 cells released from the high density state peak in mid 
S phase 30 hours later, suggesting that the high density state is located 22.5 hours away from 
G1/S border. At this stage we cannot clearly define the entry  location of G0 into G1 phase. If 
most of the high density cells represent a G0 population, then the G0 to G1 entry point is 
located 22.5 preceding the G1/S border. In our results, a transient spike of c-Myc protein 
expression occurs after release of MCF-7 cells from the high density, with its peak at 90 min 
(Melkoumian, Z. and Strobl, J., 1999), 1.5 hours prior to the D point. c-myc is an early 
response gene, whose rapid induction is essential for the cells to progress from G0 to G1 and 
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progress through early G1 phase of the cell cycle. Inhibition of c-myc using antisense 
approaches causes arrest of MCF-7 cells in a G1/G0 state (Watson, P.H. et al, 1991). c-Myc 
protein acts as a transcription factor to activate expression of so called delayed-response 
genes, such as cyclin D1, CDK4, cdc25A, whose products are necessary for G1 to S 
progression.  
In our model, quinidine causes rapid suppression of c-myc gene expression, which 
prevents progression of cells through the G1 phase, perhaps due to preclusion of Myc-
dependent events later in G1. Myc-dependent events may include the synthesis of delayed-
response genes, listed above, as well as others, whose presence is essential for progression of 
the cells through the D point. As a result, we hypothesize, cells are arrested in the D point. 
Washout of the quinidine would allow for Myc-dependent transcription to occur, and cell 
progression through G1 to S phase. In fact, Shiyi Wang showed a significant increase in 
cyclin D1 mRNA levels 12 hours after quinidine washout (Shiyi Wang, thesis, 1996). 
Unfortunately, she did not examine the earlier time points, to establish how soon after 
quinidine washout cyclin D1 mRNA levels begin to rise. In accordance with this increase in 
cyclin D1 mRNA, Zhou, Q. showed an accumulation of hyperphosphorylated form of pRb 24 
hours after the release of cells from high density, although he did not test pRb 
phosphorylation status between 12 and 24 hours (Zhou, Q. et al, 2000). Collectively, these 
data are consistent with a model, where an early induction of c-myc gene during G0 to G1 
and early G1 progression allows for the synthesis of delayed cell cycle regulatory proteins, 
that are essential for the progression through the D point. Inhibition of this c-myc induction 
by quinidine prevents transcription of c-myc regulatory genes and consequently, cells become 
arrested at the D point.  
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3. c-myc Gene 
3.1.   c-myc is a protooncogene 
A major contribution towards understanding the mechanisms of tumorigenesis has 
been the discovery of protooncogenes and tumor suppressor genes. Protooncogenes or c-
oncogenes (cellular homologues of oncogenes) are genes that are normally involved in the 
regulation of cell proliferation and can lead to the cancer when they are abnormally 
expressed in the cell. A mutated, cancer-causing version of a protooncogene is called an 
oncogene. Oncogenes were first isolated as part of small genomes of RNA tumor viruses, 
called acute transforming retroviruses (Bishop, J.M., 1983). These viruses efficiently 
transform cells in culture and in animals. It was then found that oncogenes carried by those 
viruses were responsible for their transforming capabilities. Originally, oncogenes were 
thought to be an innate part of the viral genome. Only later, when similar, but nonidentical, 
copies of the oncogenes were found in normal vertebrate cells, did it become clear that viral 
oncogenes arose as a consequence of genetic recombination between retroviruses and 
protooncogenes (Bishop, J.M., 1983). Placement of those protooncogenes in the path of 
strong viral promoters or their oncogene-converting mutation within the viral genome would 
cause continuous, uncontrolled activation of their normal functions in infected cells. Since 
most protooncogenes are involved in the regulation of some aspect of cell proliferation, their 
uncontrolled expression would lead to cellular transformation. To date, more than 70 
oncogenes have been identified. Tumor suppressor genes are genes that negatively regulate 
cell proliferation and the loss of their function by mutation can contribute to the development 
of cancer.  
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 The myc gene was originally identified as the oncogene v-myc (viral myc) of the 
MC29 avian myelocytomatosis virus (AMV) (Sheiness, D. et al, 1978, Sheiness, D. and 
Bishop, J., 1979). This retrovirus induces carcinomas, endotheliomas, sarcomas, and the 
leukemic disorder myelocytomatosis (hence myc) in susceptible birds. They transform 
fibroblasts and macrophages in tissue culture (Graf, T. and Beug, H., 1978). The c-myc gene 
was first isolated as the chicken cellular homologue of v-myc (Vennstrom, B. et al, 1982). 
Subsequently the human, mouse, and rat c-myc genes were cloned and characterized (Dalla-
Favera, R. et al, 1982; Stanton, L.  et al, 1984, Hayashi, K. et al, 1987). It was soon 
recognized that activated, oncogenic c-myc is a key transforming agent in the etiology of 
human Burkitt's lymphoma (Dalla-Favera, R. et al, 1982; Varmus, H.E., 1984). Altered c-
myc expression has been also shown in a wide variety of human tumors including breast, 
colon, and cervical carcinomas, small cell lung carcinomas, osteosarcomas, glioblastomas, 
and myeloid leukemias (Marcu, K., et al, 1992; Spencer, C., et al, 1991). Soon after the 
discovery of the c-myc gene, two other genes N-myc and L-myc were identified as amplified 
myc-related genes in human neuroblastoma and small cell lung carcinoma, respectively. The 
myc family of oncogenes currently consists of three well-characterized members: c-myc, N-
myc, L-myc and two additional genes, B-myc and S-myc, that have been identified only in 
rodents. The c-, N-, and L-myc genes share similar genomic organization and the 
corresponding proteins contain several regions of high sequence homology. The genomic 
structures of both S- and B-myc have diverged significantly from the other members of the 
family and their promoters are not well characterized at present.  
c-Myc and cell transformation  Regulated c-myc gene expression is critical for controlled 
cell proliferation, whereas deregulated expression of c-myc is a characteristic of tumor-
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derived cells. Genetic alterations leading to oncogenic activation of c-myc include gene 
amplification (Favera, D. et al, 1982), chromosomal translocation (Magrath, I., 1990), 
proviral insertion (Payne, G. et al, 1982), and retroviral transduction (Fulton, R. et al, 1987). 
Also, changes in Myc protein levels by point mutation in c-myc coding sequence have been 
reported in several tumors (Bhatia, K et al, 1993). Alterations in c-myc expression have been 
demonstrated in many types of cancer, including Burkitt’s lymphoma, myeloid and plasma 
cell leukemia, breast carcinoma, cervical carcinoma, small cell lung carcinoma, colon 
carcinoma, osteosarcoma, and glioblastoma (Cole, M.D. et al, 1986; Spencer, C. and 
Groudine, M., 1991; DePinho, R. et al, 1991). More direct evidence for the role of c-myc in 
abnormal cell growth comes from studies of transformed cells and transgenic animal models. 
Myc is capable of transforming fibroblast cell lines in vitro (Small, M. et al, 1987; Stone, J. 
et al, 1987) and established cells expressing activated c-myc form tumors in animals (Keath, 
E.J., et al, 1984).  Transgenic animal models have demonstrated convincingly that 
deregulated expression of Myc induces tumorigenesis (Henriksson, M. and Luscher, B., 
1996). Two groups created transgenic mouse strains harboring c-myc genes linked to either 
the mouse mammary tumor virus (MMTV) long terminal repeat (Stewart, T.A. et al, 1984) or 
the immunoglobulin heavy-chain enhancer (Adams, J.M. et al, 1985). In the first group, the 
mice developed mammary adenocarcinomas at high frequency, but only during the second or 
third pregnancy. In the second group, virtually all animals developed B-cell lymphomas at 
six-to-eight weeks of age, apparently due to the tissues-specific expression of the oncogene.  
These data suggest an important role of c-myc in tumorigenesis. However, the mechanisms 
by which c-Myc cause transformation remains unknown, although it has been shown that c-
Myc transactivates promoters of several growth promoting genes.  
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The goal of these studies was to understand the molecular mechanisms of c-myc gene 
regulation by quinidine in human breast cancer cells. The following sections of the 
introduction focus on a review of structure, functions, and regulation of the c-myc gene. 
 
3.2.  c-myc gene organization 
The human c-myc gene has been mapped to the 8q24 locus of the chromosome 8 
(Taub, R. et al, 1982). It consists of three exons: an untranslated first exon (exon I) and two 
protein coding exons (exons II and III). A schematic diagram of the c-myc gene organization 
is shown in Figure 4. The c-myc gene has 2 major promoters P1 and P2 located 161 
nucleotides apart in exon I. Transcription initiated at P1 and P2 produces 2.4 and 2.2 kb c-
myc transcripts, respectively. These transcripts account for 95% of total c-myc mRNA. Two 
other promoters: P0, located 500 bp upstream of P1 and P3, located in the intron I give rise to 
less then 5% of c-myc mRNA each. Both P1 and P2 contain a consensus TATA box element. 
A strong consensus initiator element (Inr) occurs only at the P2 transcription start site. A 
number of different regulatory sequences have been described in the 5' upstream promoter 
region, in the 5' and 3' untranslated regions, and within intron I. Regulation of c-myc 
expression is highly responsive to environmental signals. Some of these regulatory domains 
are shown in Figure 4 and their role in c-myc gene regulation will be discussed in the later 
section of the introduction.  
There is only one open reading frame (ORF) in all c-myc mRNA species. It starts at 
the canonical AUG initiation codon located at the 5' end of exon II and codes for the major 







Figure 4.  c-myc gene organization. 
 
Exons 1,2, and 3 are represented by open rectangles. Shaded region shows the untranslated 
portion of the exon 1. Transcription start sites, P0, P1, P2, and P3 are shown by arrows. A 
more detailed diagram of the P1 and P2 promoter regions is shown in the lower portion of the 
figure. Positions of several regulatory regions in respect to the start site for P1 promoter are 
shown in black rectangles. CUG, AUG- translation initiation sites, polyA1 and 2- 
polyadenylation sites, TATA = TATA boxes, TCE = TGFβ1 control element, Sp1 and E2F = 
Sp1 and E2F binding sites, ½ ERE = half site of canonical estrogen responsive element, CT-
box = CT-rich element, MBP-1 = binding site for the c-myc promoter binding protein-1, ERR 
= estrogen responsive region, Inr = initiator element.  
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1984). A minor protein species of 67 kDa is also observed. The translation of 67 kDa Myc 
protein begins at a cryptic start codon CUG located at the 3' end of exon I in frame with the 
previous ORF. The major translation product, p64, consists of 439 amino acids, p67 contains 
an additional 14 amino acids at the N-terminus of the p64 sequence (Hann, S. et al, 1988).  
Both products of c-myc gene (p64 and p67) are highly conserved nuclear phosphoproteins 
with a half-life of about 20-30 min (Luscher, B and Eisenman, R., 1990).  The relative 
abundance of p67 versus p64, also known as Myc 1 and Myc 2, varies among tissues and cell 
lines, with the p64 species being the major isoform in most cases. A third isoform of c-Myc 
protein, termed Myc-S (short), has been described recently (Spotts, G.D.1997). This protein 
originates from the translation initiation site approximately 100 amino acids downstream of 
the N-terminus and lacks Myc transcription activation activity. 
 
3.3.  c-Myc protein structure 
Both Myc proteins (p64 and p67) contain several structural domains characteristic of 
the transcription factors. The first 143 amino acids of the amino terminus comprise the  
transactivation domain (TAD) that contains two highly conserved Myc boxes (Mb): Mb I 
(amino acids 45 to 63) and Mb II (amino acids 129 to 141). The later is essential for all 
known Myc biological activities and is conserved among all Myc family members. Myc also  
contains two nuclear localization sequences (NLS): a primary motif at amino acids 320- 328 
and a secondary signal from 364-374. The C-terminus of Myc contains three important 
domains: 1) the basic region (BR) (amino acids 355-368) implicated in specific DNA 
sequence recognition and binding, 2) the helix-loop-helix (HLH) (amino acids 368-410) and 
3) the leucine zipper (LZ) (amino acids 411-439) responsible for specific heterodimer 
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formation between Myc and its binding partner Max (c-myc associated protein x). 
Contiguous BR-HLH-LZ motifs are characteristic of transcription factors that bind to 
specific DNA sequences. 
  Myc proteins can be phosphorylated at multiple sites by casein kinase II (CKII), 
mitogen activated protein kinase (MAPK), p34cdc2 kinase, and glycogen synthase kinase 3  
(Alvarez, E. et al., 1991; Henriksson, M et al, 1993; Pulverer, B. et al, 1994; Seth, A. et al, 
1992). Of these sites, Thr 58 and Ser 62 appear to be the most functionally relevant, although 
there are conflicting data published about the role of Thr 58/Ser62 phosphorylation in Myc 
transcriptional activity. More investigations are required to clarify the importance of 
phosphorylation in regulation of Myc functions. 
 
3.4.  Myc functions: Regulation of the cell cycle, cellular differentiation, and apoptosis 
As has been discussed earlier, c-myc gene product belongs to the family of transcription 
factors that bind as dimers to the specific DNA sequences on the target genes. Our 
understanding of molecular functions of c-Myc has significantly advanced with the discovery 
of the c-Myc dimerization partner Max. Max was originally identified by screening a human 
cDNA expression library with a radiolabeled fusion protein containing the c-Myc carboxy 
terminus (Blackwood, E. and Eisenman, R., 1991). Similarly to c-Myc, Max contains 
contiguous BR-HLH-LZ motifs, and can form heterodimers with c-Myc, N-Myc, L-Myc, 
members of MAD family of proteins, as well as homodimers with itself. All these complexes 
bind to the same E-box sequences, CACGTG and CACATG, as well as to several low-
affinity, noncanonical DNA sequences (Prendergast, G.C. et al., 1991; Blackwell, T.K. et al, 
1990; Blackwell, T. K., et al, 1993). Binding of Myc-Max heterodimers to the E-box 
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sequences causes transactivation of Myc target genes in most cases, whereas Max-Max or 
Max-Mad dimers, lacking transactivating function, may block the biological effects of Myc-
Max dimers by competitive occupancy of the binding sites. 
 c-Myc and cell cycle.  In general, c-myc expression is correlated with the proliferative 
potential of the cell. Cells constitutively expressing high levels of c-Myc have reduced 
growth factor requirements (Daczmarek, L. et al, 1985; Sorrentino, V. et al, 1986; Stern, D. 
et al, 1986), spend less time in G1 phase (Karn, J. et al, 1989), and cannot become quiescent 
(Kohl, N. and Ruley, H. 1987). In quiescent cells, c-myc expression is almost undetectable. 
Upon mitogenic stimulation there is a rapid and transient burst in both c-myc mRNA and c-
Myc protein expression as cells enter the G1 phase, followed by a gradual decline to low but 
detectable steady-state levels in proliferating cells (Campisi, J. et al, 1984; Kelly, K. et al, 
1983; Moore, J. et al, 1987). Since this rapid induction of c-myc transcription occurs 
independently of de novo protein synthesis, it was suggested that c-myc is an immediate 
response gene, such as c-fos and c-jun, directly downstream of mitogenic signaling cascades. 
A number of studies demonstrated that sharp induction of c-myc expression following serum 
stimulation of quiescent cells is a prerequisite for normal transition from G0 to G1 and G1 to 
S phase in nontransformed cells (Eilers, M. et al, 1989; Heikkila, R. et al, 1987; Shichiri, M. 
et al, 1993). Whereas c-Myc plays a key role during the G0/G1 to S phase transition, 
continuous low-level c-myc expression throughout the cell cycle suggests its importance in 
other phases. Withdrawal of growth factors or treatment with differentiation-inducing agents 
causes c-myc mRNA and protein expression to decrease to almost undetectable levels. In 
contrast to c-Myc, expression of its partner, Max, is expressed at a constant low levels 
throughout the cell cycle. Max has a half-life of 24 hours (Blackwood, E., Lucher, B., 1992), 
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which implies that changes in Myc levels during the cell cycle play an important role in the 
regulation of Myc-Max heterodimers. A schematic diagram of the expression levels of c-
Myc, Max, and Mad family of proteins during the cell cycle is shown in Figure 5. 
c-Myc and cell differentiation c-Myc also plays an important role in cellular 
differentiation. It has been shown in many cells that down-regulation of c-Myc expression 
accompanies terminal differentiation and permanent withdrawal from the cell cycle. 
Blocking c-Myc activity using antisense oligonucleotides, ectopic expression of Max, or 
expression of dominant negative c-myc gene can induce differentiation of HL-60 
(promyelocytic leukemia), F9 (teratocarcinoma), K562, and MEL (murine erythroleukemia) 
cells (Canelles, M. et al, 1997; Griep, A and Westphal, H., 1988; Holt, J. e al, 1988; 
Prochownik, E. et al, 1988). Conversely, independent studies showed that ecotpic c-Myc 
expression from a transfected gene is sufficient to block the induction of differentiation in 
MEL, 3T3-L1 preadipocyte, F9, PC12 neuronal, and U-937 monoblastic cell lines (Coppola, 
J.A., and Cole, M.D., 1986; Dmitrovsky, E. et al, 1986; Freytag, S., 1988; Larsson, L., et al, 
1988; Maruyama, K. et al, 1987, Onclercq, R. et al, 1989; Prochownik, E. and Kukowska, J., 
1986). These data suggest that suppression of c-Myc may be necessary for differentiation of 
certain cell types, perhaps because withdrawal from the cell cycle by c-Myc down-regulation 
is essential for terminal differentiation. 
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Figure 5. Expression pattern of Myc family proteins in cycling and differentiated cells. 
 
Expression levels of proteins are shown in solid lines of different colors. Myc/Max dimers 
bind to the E-box sequence and transactivate Myc-target genes. Max/Max, Max/Mad, 
Max/Mxi1 dimers bind to the same E-box sequence, but due to the lack of transactivation 
domain, block the biological effects of Myc/Max dimers by competitive occupancy of their 
binding sites. 
Henriksson, M. and Luscher, B., 1996. 
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    c-Myc and apoptosis.  A most paradoxical discovery from the work on c-myc was the 
finding that under certain circumstances c-Myc is able to induce apoptosis or programmed 
cell death. Separate studies in fibroblasts (Evan, G.I. et al, 1992) and in haemopoietic cells 
(Askew, D.S. et al, 1991), revealed that constitutive expression of the Myc required the 
presence of growth/survival factors in order for cells to proliferate. Withdrawal of serum 
from fibroblasts or removal of interleukin 3 from haemopoietic cells expression Myc caused 
cells to undergo apoptosis. The mechanisms of Myc-induced apoptosis are poorly 
understood. Several genes involved in the regulation of apoptosis, such as p53, Bax, and p21 
contain c-Myc responsive regions in their promoters, but the role of these genes in Myc-
induced apoptosis remains unclear. The pro-apoptotic function of c-Myc resembles that of 
several other oncogenes, such as E2F and E1A and might represent a safeguard mechanism 
important during organism development. For example, increased levels of c-Myc during 
development would allow for the proliferation of only those cells that receive the appropriate 
survival signals. Otherwise, a Myc over-expressing cell, representing a potential danger to 
the organism, would be eliminated by apoptosis. It has been hypothesized that c-myc 
activation may facilitate tumorigenesis in cells in which a survival pathway was already 
activated by mutation. 
In summary, these data suggest a critical role of c-myc gene in the regulation of the 
cell cycle progression, cellular differentiation and apoptosis. Deregulated expression of c-
myc in a variety of tumors, the ability of exogenously expressed c-myc to transform 
established cell lines in vitro and induce tumors formation in transgenic animals indicate an 
important role of c-myc gene in tumorigenesis. Although the molecular mechanisms leading 
to deregulated expression of c-myc gene in tumors are well understood, the precise cellular 
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function of the c-Myc protein has remained an enigma, despite continuous efforts for more 
then a decade to identify these functions. Some insight on these functions has been brought 
with the identification of c-myc target genes, which are discussed in the following section. 
 
3.5.  Myc target genes 
The role of Myc protein as a transcription factor was proposed long before any of its 
target genes were identified, on the basis of certain structural features of the Myc protein. 
The contiguous BR-HLH-LZ motifs in Myc are characteristic of a large class of transcription 
factors, including AP4, the upstream stimulatory factor (USF) and the immunoglobulin-
enhancer, µE3-binding proteins (Johnson, P. and McKnight, S., 1989; Beckmann, H. et al, 
1990; Carr, C. and Sharp, P., 1990; Gregor, P. et al, 1990).  
The following criteria have been used to identify Myc target genes: 
1. Presence of functional Myc-Max binding sites within the putative target gene. 
2. Pattern of gene expression correlates with that of the Myc during transition from 
quiescence to proliferation and/or differentiation. 
3. Modulation of candidate gene's mRNA levels upon induction of Myc, or activation of 
conditional Myc-ER fusion protein. In the latter case, the changes in mRNA should be 
independent of de novo protein synthesis. 
4. Functional role of the candidate target gene in c-Myc-mediated cell transformation and/or 
proliferation. 




A partial list of Myc target genes is shown in the Table 1. Products of some of these 
genes function as key cell cycle regulatory proteins (cyclin D1, cyclin A, CDK4, p15Ink4b, 
p21WAF1, cdc25A phosphatase, gadd 45). Others are involved in the regulation of cell 
growth and metabolism (DHFR, LDH-A, CAD, ODC), transcription process (E2F2, eIF-2α, 
eIF-4E), or apoptosis (p19 ARF, p53, p21WAF1). The data on cyclin D1 is very 
controversial, with some reports showing up-, others down-regulation of cyclin D1 
expression by c-Myc (Daksis, J.I. et al, 1994; Philipp, A. et al, 1994). Myc can also 
negatively regulate its own expression (autoregulation) via the Initiator element located 
within P2 promoter. In general, transcriptional activation of Myc-target genes by Myc-Max 
heterodimers occurs via the E-box elements, whereas the Initiator element is responsible for 
Myc-induced transcriptional repression. Both mechanisms are important for Myc-mediated 
cellular transformation (Dang, C.V. et al, 1999). 
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E-box (5'untranslated) Pyrimidine biosynthesis 
p19 ARF 
 
Up Guess Apoptosis 
p15Ink4b 
 
Down Initiator (P2 promoter) Cell cycle regulation 
p21WAF1/CIP1 
 
Down Promoter  Cell cycle regulation 
cdc25A Up Guess/E-box (intron II) Cell cycle regulation 
 
Cyclin A Up Guess Cell cycle regulation 
 
Cyclin D1 Up/ 
Down 
 
E-box (promoter)/differ and 
Initiator 
 
Cell cycle regulation 
CDK4 Up E-box (promoter) Cell cycle regulation 
 
DHFR Up E-box (promoter) Growth and metabolism 
 
E2F2 Up E-box (promoter) Transcription factor 
 
eIF-2α Up Guess Transcription initiation factor 
 
eIF-4E Up Guess/ E-box (promoter) Transcription initiation factor 
 





Up Guess/E-box (promoter) Immortality 




Down E-box (promoter) Cell adhesion/metastasis 
LDH-A Up E-box (promoter) Metabolic enzyme 
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ODC Up E-box (intron I) Polyamine biosynthesis 
 




Techniques used to identify putative c-Myc genes: 
 
Guess - expression of target gene correlates with c-myc expression during transition from 
quiescence to proliferation and/or differentiation. Functional importance for Myc-
mediated phenotypes. 
Differ - differentially expressed genes upon enforced expression of c-Myc in the absence 
of de novo protein synthesis. 
E-box - presence of functional Myc/Max binding sites in the promoter or other region of 
the candidate gene. 
Initiator - presence of functional initiator element in the promoter of the candidate gene. 
Up and Down indicate effect of c-Myc on the expression levels of the gene. CAD-
carbamoyl phosphate synthase, ODC - ornithine decarboxylase, LDH- lactate 
dehydrogenase, DGFR - dihydrofolate reductase, eIF-4E and eIF-2α - eukaryotic 
initiation factors. 
Reviewed by Dang, C.V. et al, 1999; Galaktionov, K. et al, 1996; Philipp, A. et al, 1994; 
Jones, R.M. et al, 1996; Reisman, D. et al, 1993; Shim, H. et al, 1997; Belo-Fernandez, 
C. et al, 1993; Facchini, L.M. et al, 1997; Jansen-Durr et al, 1993; Daksis et al, 1994; 








3.6.  Role of c-Myc in breast tumorigenesis 
c-Myc is one of the most common oncogene aberrations in breast cancer (Spaventi, 
R. et al, 1993; Berns, E. et al, 1992; Garcia, I. et al, 1989; Escot, C. et al, 1986). According to 
one study, c-myc amplification is a better prognostic marker than is c-erbB-2 (Berns, E. et al, 
1992). In human breast cancers, c-myc is amplified in approximately 16%, rearranged in 
approximately 5%, and over-expressed in the absence of gross locus alteration in nearly 70 % 
of all cases, suggesting its importance in the genesis and/or progression of breast cancer 
(Nass, S.J. and Dickson, R.B, 1997; Deming, S.L. et al, 1999). 
 
3.6.1. Experimental evidence for the role of c-myc in breast tumorigenesis in breast cell lines 
models 
 Constitutive expression of c-myc has been shown to partially transform both mouse 
and human mammary epithelial cells (MECs), such that they grow in soft agar (anchorage-
independent growth) in response to epidermal growth factor (EGF) and transforming growth 
factor α (TGFα), and are no longer as dependent upon these growth factors for anchorage-
dependent growth as are the parental, non-transformed cells (Telang, N.T. et al, 1990; 
Valverius, E.M. et al, 1990). Manipulation of the expression of c-myc gene in cell lines has 
confirmed that c-myc is critical for the growth of breast cancer cells (Watson, P.H. et al, 
1991). In estrogen receptor positive, hormone-dependent breast cancer cells (MCF-7 and 
T47D), c-myc gene is directly regulated by estrogen (Dubik, D. and Shiu. R.P, 1988; Dubik, 
D. and Shiu, R.P., 1992). In vitro nuclear run-on transcription assays demonstrated estradiol-
stimulation of c-myc gene transcription in MCF-7 cells, increasing c-myc mRNA 
transcription more than 10-fold within 20 min. Estradiol had no effect on the c-myc mRNA 
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half-life of about 20 min (Dubik, D. and Shiu, R.P., et al, 1988). Northern blot analysis 
showed a similar pattern. The maximum c-myc mRNA accumulation of 12-fold, was 
achieved one hour after addition of estradiol to MCF-7 cells. In a search for the mechanism 
of estrogen-mediated activation of c-myc, a 116-bp estrogen responsive region (ERR) was 
identified within the c-myc promoter (Dubik, D. and Shiu, R.P., 1992). This region contains 
half-site of consensus ERE as well as  Sp1 transcription factor binding site (GC-rich element) 
(Figure 4). The presence of the GC-rich element may be important to estrogen-mediated 
regulation of the c-myc promoter, since activation of several estrogen-responsive genes by 
Sp1/ER complex as that bind to GC-rich element has been reported (Duan, R. et al, 1998; 
Sun, G. et al, 1998; Qin, C. et al, 1999). In ER-negative MDA-MB-231 human breast cancer 
cell line, c-myc is expressed at high constitutive levels and its expression is independent of 
estrogens (Dubik, D. et al, 1987). Antisense c-myc oligonucleotides inhibit both estrogen-
dependent and estrogen-independent growth of MCF-7 and MDA-231 cells lines, 
respectively (Watson, P.H. et al, 1991). These studies in human breast cancer cell lines 
indicate that Myc is important for cell growth (Shiu, R.P. et al, 1993).  
 
3.6.2. Experimental evidence for the role of c-myc in breast tumorigenesis in transgenic 
animal models 
  Three groups have independently developed transgenic mice that express the c-myc 
oncogene in a mammary associated (mouse mammary tumor virus, MMTV-c-myc) or 
mammary specific (whey acid protein gene promoter, WAP-c-myc) context (Stewart, T. et al, 
1984; Schoenenberger, C. et al, 1988; Sandgren, E et al, 1995). WAP-c-myc transgenic mice, 
developed by both groups demonstrated a high incidence of mammary tumors: 
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adenocarcinomas in case of Schoenenberger's group or solid carcinomas in case of 
Sandgren's group. In the both laboratories, tumor incidence approached 100% in multiparous 
animals. In contrast, all virgin animals remained tumor-free over the fourteen months 
observation period. These findings are as expected, on the basis of the temporal window for 
the hormone-driven activity of the whey acid protein (WAP) gene promoter. The group, 
which developed MMTV-c-myc transgenic mice reported 100% incidence of mammary 
adenocarcinomas in multiparous animals (Stewart et al, 1984). Interestingly, WAP-c-myc and 
MMTV-c-myc transgenic mice displayed a lengthy tumor latency, and strong dependency 
upon pregnancy for tumor development. These data suggest that c-myc contributes, but in not 
sufficient to induce mammary tumorigenesis. Two bitransgenic mice models: MMTV-c-
myc/MMTV-v-Ha-ras developed by Sinn's group (Sinn, E. et al, 1987) and MMTV-c-
myc/MT-tgfα developed by Dickson's group (Amundadottir, L. et al, 1995; Sandgren, E. et 
al, 1995) demonstrated that deregulated c-myc expression synergized with deregulated v-Ha-
ras or tgfα expression to both accelerate mammary tumorigenesis and abrogate the 
requirement for pregnancy in this process. Bitransgenic animals from the second group 
showed the complete absence of normal mammary tissue and the ability of bitransgenic 
mammary tissue from three-week-old mice to form tumors in athymic mice. These results 
suggest that c-myc and tgf α, two important mammary gland relevant genes, are capable of 
synergistically transforming the mammary epithelium, apparently requiring minimal, if any, 
additional genetic alterations (Amundadottir, L. et al, 1995 and 1996). 
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3.7.   Regulation of c-myc gene expression 
Expression of the c-myc gene is controlled by transcriptional initiation, transcriptional 
elongation and posttranscriptional processes. 
 
3.7.1. Regulation of transcriptional initiation  
c-Myc is transcribed from multiple, independently regulated transcription initiation 
sites. Two major promoters, P1 and P2, positioned 161 bp apart, give rise to 75-90% of c-
myc mRNA. Two minor promoters, P0 and P3, lacking canonical TATA boxes give rise to 
less than 5% of c-myc mRNA each.  
Studies of c-myc chromatin have revealed multiple DNase I hypersensitive sites 
(DH), some of which overlap with cis-acting c-myc regulatory elements. DNase I 
hypersensitive sites mark perturbations in the regular chromatin structure that are usually 
caused by the binding of regulatory proteins to DNA. The locations of DH sites, relative to 
P1 promoter and their putative roles in c-myc regulation are listed in the Table 2 (Spencer, C. 
and Groudine, M., 1991; Siebenlist, U. et al, 1984). 
The DNA cis-acting elements are nucleotide sequences, usually located upstream of 
the gene coding region, which are recognized and bound by specific regulatory transcription  
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Locations are given in respect to P1 promoter. 
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factors (trans-acting proteins), thereby causing the gene to respond to various regulatory 
agents. A large body of work has been done to identify cis-acting elements of the c-myc 
promoter that are involved in regulation of transcriptional initiation. Most of what we know 
about c-myc regulatory elements has been identified by assaying the effects of promoter 
sequence deletions on promoter activity within transfected cells. In this deletion/transfection 
assay a series of c-myc deletion mutants linked to reporter genes, e.g. luciferase or 
chloramphenicol acetyl transferase (CAT), were transiently transfected into mouse or human 
cell lines and the relative promoter activities in different mutant constructs were analyzed. 
The nature of protein-DNA interactions in a putative responsive region were assayed by 
electrophoretic mobility shift assay (EMSA). Some of cis-acting elements identified within c-
myc promoter employing the described methods are listed in the Table 3. The locations of the 
elements are given relative to the P1 promoter. 
 
3.7.2. Regulation of transcriptional elongation 
Regulation of gene expression at the level of transcriptional elongation occurs in both 
prokaryotic and eukaryotic systems. Transcriptional elongation mechanism plays an 
important role in regulation of a number of protooncogenes, including c-myc, L-myc, c-myb, 
c-fos, and c-mos. The region necessary for transcriptional blockage within c-myc has been 
defined by a number of studies using the in vitro run-on assay. Bentley and Groudine were 
the first to describe the c-myc transcriptional block phenomenon with their work on the 
human c-myc gene (Bentley, D. and Groudine, M., 1986). A 95 bp sequence ending 35 bp 5' 
of the exon1/intron1 boundary of the human c-myc gene was sufficient to effect premature 
transcriptional termination in Xenopus oocytes when cloned downstream of the HSV tk 
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promoter (Bentley, D and Groudine, M., 1988). In wild-type c-myc templates, transcripts 
terminate prematurely at two thymine-rich sequences: a T7 stretch 20 bp upstream and a 
T4/T7 stretch 30 bp downstream of the exon I/intron I boundary, respectively. c-Myc 
transcription has been shown to be extremely pliable to various growth factors, mitogens and 
differentiation agents that may act by altering elongation. For example, a rapid and dramatic 
increase in c-myc transcriptional blockade was observed upon exposure of HL60 cells to 
retinoic acid (RA) (Asselin, C. et al, 1989), DMSO (Eick, D. and Bornkamm, G., 1986), or 
vitamin D (Simpson, R. et al, 1987). The intensity of DH IV site within intron 1 was shown 
to increase with block of transcriptional elongation. The 10-fold increase in the block of 
transcriptional elongation in HL60 cells treated with DMSO occurred within 30 min of 
treatment (Eick, D. and Bornkamm, G., 1986). Between 24 and 48 hours after treatment, the 
level of transcriptional initiation in exon I also declined. These experiments suggest that the 
block of transcriptional elongation can control c-myc mRNA levels during cellular 
differentiation. Also, an increase in c-myc steady-state mRNA, partially due to a release of 
the elongation block, occurs in quiescent normal peripheral blood T lymphocytes stimulated 
by phorbol myristate acetate (PMA) (Lindsten, T. et al, 1988). 
In summary, these data suggest that regulation of c-myc transcription can be also 
achieved at the levels of transcriptional elongation in addition to initiation. It is possible that 
the abnormal regulation of c-myc expression that occurs in tumors may, in some cases, result 
from disruption of the block of transcriptional elongation process. 
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region from -60 to -37  
Essential for P1 transcription (Nishikura, K., 1986). It 
contains a GC-rich sequence CCGCCC (-38 to -43) that 
binds Sp1 and Sp3 transcription factors (Majello, B. et al, 
1995). Sp1 and Sp3 proteins belong to a multigene family 
whose members have similar, if not identical DNA binding 
activities (Hagen, G. et al, 1992). Both Sp1 and Sp3 bind to 
GC-rich and CT-rich boxes with comparable affinities 
(Majello, B. et al, 1995). In vivo transfection experiments 
have shown that Sp1-mediated transactivation of Sp1-
responsive promoters are repressed by Sp3.  
 
five tandem CT-boxes 
(CCCTCCCC) located  101 
bp upstream P1 
Required to promote transcription from P1 and for maximal 
activity of P2 (DesJardins, E. and Hay, N., 1993). Mutations 
of these CT-boxes decreases the absolute and relative 
activities of P1 and P2 promoters. CT-boxes were shown to 
bind Sp1/Sp3 (DesJardins, E. and Hay, N., 1993) as well as 
ZF87/MAZ transcription factors. 
 
a single copy of the CT-box 
(CCTCCCTCCCT) in an 
inverted orientation located 
53 bp upstream P2 
 
This element has an inhibitory effect on P1 and is required 
for P2 transcription, respectively. It can bind both Sp1/Sp3 
and MAZ transcription factors (DesJardins, E. and Hay, N., 
1993). 
two E2F binding sites, 
GATCGCGC (+122 to 
+129) and GCGGGAAA 
(+99 to +106) 
 
Cooperate with Sp1 in transactivating c-myc P2 promoter 
(DesJardins, E. and Hay, N., 1993; Majello, B. et al, 1995). 
 
a 116 bp estrogen 
responsive region (ERR) 
located between +25 and 
+142 
Important for estradiol-induced activation of c-myc 
promoter in MCF-7 and HeLa cells (Dubik, D. and Shiu, R., 
1992). This region contains half site of consensus estrogen 
responsive element (ERE) (+76 to +80) as well as Sp1/E2F 
(+98 to +106) binding sites, which can cooperate in 
transactivating estrogen-responsive promoters (Duan, R. et 
al, 1998; Sun, G. et al, 1998; Qin, C. et al, 1999). 
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transforming growth factor 
β1 (tgf β1) control element 
(TCE) located upstream P1 
between  -63 and -83 
 
Inhibits c-myc P1 transcription initiation, possibly via the 
pRb gene product (Pietenpol, J. et al, 1991).  
 
26 bp region (-343 to - 318) Negative regulatory element. Containing binding site for 
Ap1 transcription factor (Takimoto, M. et al, 1989). 
 
CGCTGAGTA region from 
+127 to +135, just 
5'upstream of the P2 TATA 
box 
Binds MBP-1 (myc promoter binding protein 1), and 
appears to be a negative regulator of c-myc transcription 




The locations of the elements are given in respect to P1 promoter unless otherwise specified.  
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4. Role of c-myc in TGF-β Signaling 
Transforming growth factor β (TGF-β) is a prototypic member of a large family of 
cytokines that plays an important role in a variety of biological processes, including cell 
division, differentiation, adhesion, movement, and death  (Derynck, R. and Feng, X., 1997). 
TGF-β has a strong growth inhibitory effect on epithelial and other cell types. It is not 
surprising, that TGF-β signaling is lost in some cancers by inactivation of TGF-β signal 
transduction components (Massague, J. et al, 2000). There are three families of TGF-β 
receptors, type I (RI), II (RII), and type III (RIII) receptors. The RI and RII are 
transmembrane serine/threonine kinases with a single transmembrane domain. Free receptors 
exist in cell membrane as homodimers. Binding of the ligand (TGFβ-1, -2, or -3) to the type 
II receptor triggers formation of heteromeric type I-type II receptor complex, that propagates 
the TGF-β responses (reviewed in Derynck, R. and Feng, X., 1997). In the resulting 
complex, the type II receptor phosphorylates and activates the type I receptor. Activated type 
I receptor then phosphorylates the intracellular mediators of TGF-β signaling Smad2 or 
Smad3 proteins at SSXS motif present in their C-terminal domains.  This, in turn, triggers the 
oligomerization of Smad2 or –3 with their common partner, Smad4 (Nakao, A. et al, 1997; 
Lagna, G. et al, 1996). The resulting Smad protein complexes then migrate to the nucleus, 
where they regulate the expression of TGF-β responsive genes. The RIII, also called 
proteoglycan, is the most abundant TGFβ-1 binding molecule on the cell surface. Type III 
receptor does not contain a consensus signaling motif, therefore the biological importance of 
RIII in vivo has not been defined. It has been proposed that RIII enhances TGFβ-1 binding to 
RII by directly presenting the ligand to RII (Lopez-Casillas, F. et al, 1993; Moustakas, A. et 
al, 1993). Expression of RIII restores autocrine TGFβ-1 activity in MCF-7 human breast 
 40 
cancer cells (Chen, C. et al, 1997). In epithelial cells derived from the breast, skin, and lung, 
TGF-β rapidly elevates expression of the cell cycle inhibitory proteins p15Ink4b and p21WAF1 
(discussed in the section 2.1) (Sandhu, C. et al, 1997; Hannon, G. and Beach, D., 1994; 
Reynisdottir, J. et al, 1995; Claassen, G.F. and Hann, S.R., 2000).  Interestingly, this 
response is suppressed by c-myc (Warner, B. et al, 1999; Massague, J. et al, 2000). c-myc 
itself is a target gene of TGF-β signaling. In response to TGF-β, c-myc is rapidly down-
regulated in MCF-10A human mammary epithelial cells, HaCaT keratinocytes, and other 
epithelial cell types (Chen, C. et al, 2001).  Two recent papers provided an important insight 
into the complex regulation of p15Ink4b by TGF-β and Myc (Seoane, J. et al, 2001; Staller, 
P. et al, 2001). Zinc-finger protein Miz-1, originally identified as a Myc-binding protein, 
plays the key role in that regulation. In the complex with Miz-1, Myc can bind to the initiator 
element of the p15Ink4b promoter and inhibit its transcriptional activation by preventing 
recruitment of the ubiquitous co-activator p300. Upon TGF-β treatment, Myc is rapidly 
down-regulated. This, in turn, allows for the interactions of Miz-1 with other transcription 
factors, such as Sp1, Smad3/4 on p15Ink4b promoter, which is proposed to generate a 
nucleoprotein complex that constitute a platform for the recruitment of co-activators, basal 
transcription factors, and RNA polymerase II. Hence, down-regulation of c-myc is required 
for TGF-β mediated induction of p15Ink4b. In fact, suppression of the c-myc promoter by 
TGF-β treatment through TGF-β control element (TCE) has been characterized (Pietenpol, J. 
et al, 1991). In accordance with these results, it was shown that the loss of c-myc down-
regulation in mammary epithelial cells, MCF-10A, transformed with Ras/ErbB2 oncogenes 
and MDA-MB-231 human breast cancer cell line coincides with a loss of TGF-β 
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responsiveness of c-myc promoter (Chen, C. et al, 2000). In summary, these data suggest that 




5.  Quinidine 
Quinidine is a natural alkaloid found in the bark of the South American cinchona tree. 
Of the more than 20 alkaloids found in the cinchona bark only quinidine and its stereo- 
isomer quinine are now in use. The structure of quinidine is shown below. Quinidine is used 
as an antiarrhythmic drug that acts to suppress abnormal heart rhythm, particularly atrial 
fibrillation and flutter, paroxysmal atrial trachycardia, paroxysmal ventricular tachycardia, 
and premature atrial and ventricular contractions (Katzung, B.G., 1984). These actions 
probably result to a large extent from the quinidine’s ability to block sodium channels (Craig, 
R.C. and Stitzel, R.E., 1994). Side effects include low blood pressure, skin rash, itching, 
dizziness, and blurred vision. Quinidine also has an antimalarial activity, but because of its 
superior absorption only quinine is used for the treatment of malaria. The exact mechanism 
by which quinidine and quinine exert their antimalarial activity is not known. 
Our previous studies established quinidine as an antiproliferative agent in human breast 
cancer cell lines (Woodfork, K.A., 1995; Wang, S., 1998; Zhou, Q., 2000). The studies 
reported here focused on further characterization of molecular mechanisms underlying the 
antiproliferative effects of quinidine.    
 
                                           Quinidine              
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6.  G0-G1-S Cell Cycle Regulation in MCF-7 Cells by Potassium Channel Blocking 
Drugs. 
An important role of potassium channels in regulating cell proliferation has been reported 
in a number of cell lines (reviewed by Dubois, J. and Rouzaire-Dubois, B., 1993; Nilius, B. 
and Droogmans, G., 1994). Previous studies in Dr. Strobl's and Dr. Wonderlin's laboratories 
indicate that potassium channel blocking agent, quinidine causes G1/G0 cell cycle arrest and 
inhibition of proliferation in MCF-7 human breast cancer cell line (Woodfork, K. et al, 
1995). Wodfork, K. et al, demonstrated that quinidine inhibits proliferation and causes 
G1/G0 arrest with the same dose dependence with which it depolarizes the membrane 
potential of MCF-7 cells. In addition, she identified the ATP- sensitive potassium channels 
(KATP) as the target of quinidine, since only the agents that inhibited KATP were able to 
produce G1/G0 cell cycle arrest and inhibition of proliferation (Woodfork, K., et al, 1995). 
The work by Klimatcheva, K. described a linear hyperpolarized (LH) potassium current, 
inhibited by quinidine, which is required for progression of MCF-7 cells through the G1 
phase of the cell cycle. Interestingly, this current is overexpressed in MCF-7 cells 
transformed with Ha-ras oncogene (Klimatcheva, E. and Wonderlin, W., 1999). This notion 
is consistent with the reports by other investigators showing that expression or activity of K 
channels correlates with the degree of cell proliferation in several other cell types (Wang, L. 
et al, 1997; Nilius, B. and Wohlrab, W.,1992; Reichelt, W., 1989). Collectively, these studies 
support a model where hyperpolarization of the membrane potential by transient activation of 
the linear hyperpolarized current might be required for progression through the restriction 
point in G1 (D point) and entry into S phase. Accordingly, inhibition of LH current by 
blockade of KATP in response to quinidine, will prevent hyperpolarization of membrane 
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potential and cells will become arrested at the D point. In support to this model, a large body 
of evidence has shown that progression through the cell cycle is associated with changes in 
intracellular ionic concentrations, which can be regulated by the changes in the membrane 
potential (Whitaker, M. and Patel, R. 1990; Whitfield, J. et al, 1987). Intracellular ions, in 
turn, initiate signal transduction pathways that lead to the activation of proliferation. For 
example, increase in intracellular Ca2+ activates CREB transcription factor that stimulates 
transcription of growth promoting genes (Sheng, M. et al, 1991). Several immediate-response 
genes were shown to be induced by calcium agonists (reviewed in Roche, E. and Prentki, M, 
1994). Treatment of human promyelocytic leukemia cells (HL-60) with the calcium 
ionophore A23187 caused an increase in c-myc mRNA levels to 170 % of control cells 
within an hour (Salehi, S., and Niedes, J., 1990). The putative intracellular calcium 
antagonist TMB-8 inhibited both c-myc expression and DNA synthesis in a dose-dependent 
manner in the Nb2 lymphoma cells (Murphy, P., 1988). It has also been shown that calcium 
influx is a very early signal transduction that precedes the specific induction of the c-myc 
proto-oncogene in lymphocytes (Liburdy, R., 1993).  
 The goal of studies presented here was to further understand the mechanism of G1/G0 
cell cycle arrest and inhibition of cell proliferation in response to quinidine. The molecular 
mechanism of c-myc gene regulation by quinidine in human tumor and normal breast 
epithelial cell lines were studied. Effects of quinidine on c-Myc protein and mRNA levels, as 
well as c-myc promoter activity were examined. Furthermore, the long-term effects of 
quinidine in breast tumor cell lines were tested.  
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7.   Research Objectives 
Previous studies in this laboratory demonstrated that quinidine causes early G1/G0 arrest 
and inhibits proliferation in MCF-7 cells. The goal of these studies was to understand the 
molecular mechanisms of c-myc gene regulation by quinidine in human breast cancer cells.  
 
1. In the first series of experiments I tested the hypothesis that quinidine causes rapid 
decrease of c-myc mRNA and protein levels during the G0/G1 transition in human 
breast cancer cells.  Four different breast cancer cell lines (MCF-7, MCF-7ras, MDA-231, 
MDA-435) and normal breast epithelial cell line (MCF10A) were used. 
 
2. Secondly, I tested the hypothesis that quinidine suppresses c-myc promoter activity. 
Effects of quinidine on c-myc promoter were examined in a transient reporter gene assay, 
using human c-myc promoter-luciferase constructs. Quinidine responsive region (QRR) of c-
myc promoter was described. The role of TGF β1 and Sp1/Sp3 responsive elements located 
within QRR was examined. 
 
3. Finally, I studied the long-term effects of quinidine. Three important questions were 
addressed:  
3.1 Does quinidine induce differentiation in breast cancer cells 
3.2 Does quinidine selectively inhibit growth in breast cancer, but not in normal 
breast epithelial cells 
3.3 Whether a specific down-regulation of c-myc by antisense oligonucleotides is 
sufficient to cause quinidine-induced phenotype in breast cancer cells 
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II.    MATERIALS AND METHODS 
 
1.  Materials 
1.1. Cells 
MCF-7 cells and MDA-MB-231 cells were provided by Dr. Marc Lippman 
(Lombardi Cancer Center, Georgetown University). The MCF-7 cells transformed with the 
H-ras oncogene (Kasid, A. et al, 1985) were provided by Dr. Robert Dickson (Lombardi 
Cancer Center, Georgetown University). MDA-468 cells were obtained from the American 
Type Culture Collection. MDA-MB-435 and T47D cells were provided by Dr. Mike Miller 
(Department of Biochemistry, West Virginia University) and Dr. Michael Moore 
(Department of Biochemistry, Marshall University), respectively. Normal human mammary 
epithelial cells HMEC and MCF10A were obtained from Clonetics (San Diego, CA) and 
American Type Culture Collection, respectively.  
 
1.2.  Drugs/Hormones/Oligonucleotides   
Quinidine-HCl was purchased from Sigma Chemical Co. (St. Louis, MO). 
Concentrated stock solutions (10mM) were prepared fresh for use by dissolving in sterile 
water. Seven µl of 10N HCl/ml of the stock solution was used.  Estradiol-17β (Steraloids, 
Wilton, NH) was dissolved in 95% ethanol at a concentration of 2mM and diluted 1:106 in 
the medium to get the final concentration of 2nM. TGFβ1 (R&D Systems, Minneapolis, MN) 
stock solution (2.5µg/ml) was prepared by dissolving in 4mM HCl, 1mg/ml BSA and stored 
at -20°C. c-myc antisense (5'-AACGTTGAGGGGCAT-3') and sense oligonucleotides (5'-
ATGCCCCTCAACGTT-3') were purchased from Sigma-Genosys (Woodlands, TX) and 
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diluted in sterile water to yeild concentrated stock solutions of 175 µM. The stock solutions 
were stored at -20°C for 2 months.  
 
1.3.  Plasmids   
The human c-myc probe used for Northern blots was a 9 kb EcoR1-Hind III genomic 
fragment spanning exons I and II and intron I isolated from the plasmid pHSR-1 obtained 
from the American Type Culture Collection (Alitalo, K, et al, 1983). The reporter plasmids 
containing different regions of the human c-myc promoter linked to the firefly luciferase gene 
were kindly provided by Dr. Bert Vogelstein, Johns Hopkins University (He, T. et al, 1998).  
The structures of myc-luciferase plasmids were confirmed by DNA sequencing. The human 
cyclin D1- luciferase plasmid (1745CD1-Luc) was kindly provided by Dr. Richard Pestell 
(The Albert Einstein College of Medicine, Bronx, NI) (Albanese, C., et al, 1995) 
 
1.4.  Antibodies   
The Ki-67 (MIB-1, Ab-1) antibody (Oncogene Science, Cambridge, MA) was used at 
a dilution of 1:50. The c-Myc antibody (9E10, sc-40), which reacts specifically with c-Myc 
p67 of human origin and β-catenin (E-5, sc-7963) antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA) were used at a dilution of 1:200 and 1:3000, respectively. A peroxidase-
conjugated anti-mouse IgG (sc-2005, Santa Cruz) was used as the secondary antibody at a 
1:2000 dilution for Western blots. A biotinylated anti-mouse IgG (H+L) (BA-2000, Vector 
Laboratories, Inc.) was used as the secondary antibody at a 1:125 dilution for Ki-67 
immunohistochemstry. The fluorescein-conjugated phalloidin antibody (Sigma) was used at a 
1:200 dilution of a 5 µg/0.1ml solution in the Nile Red assay. 
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1.5.  Stains  
The fluorescent lipid stain, Nile Red (Sigma) was used at a 1:10,000 dilution of a 
1mg/ml acetone solution. The Oil Red O (Sigma) stock solution was prepared by dissolving 
2.5 g of the Oil Red O in 500 ml of 98 % Isopropanol. The working solution was prepared 
fresh each time by diluting the stock solution in water at a 3:2 ratio. The working solution 
was filtered once through the P5 Fisherbrand Filter paper (09-801D, Fisher Scientific). 
 
2.  Methods 
2.1.  Tissue culture 
MCF-7 cells between passages 40-50, MCF-7ras, T47D, MDA-MB-231, and MDA-
MB-435 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(BioWhittaker, Walkersville, MD) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (HyClone Laboratories, Inc, Logan, Utah), 2 mM glutamine, and 40 µg/ml 
gentamicin. Experiments were performed in DMEM supplemented with 5% FBS. The cells 
were maintained at 37 °C in a humidified atmosphere of 94% air, 6% CO2. Cells were 
passaged every 5-6 days (about 70-80% confluent) at a 1:5 (MCF-7 and T47D) or 1:10 
(MCF-7ras, MDA-MB-231, and MDA-MB-435) ratio. Normal human mammary epithelial 
cells HMEC and MCF10A were grown in MEGM medium according to the directions from 
suppliers. HMEC were grown from frozen stocks and used for 1-3 passages only. All cells 
were counted using a hemocytometer. Cell viability was determined by trypan blue exclusion 
(0.02 % trypan blue). 
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2.2. Flow cytometry 
Cell cycle phase distribution was anyalysed using the propidium iodide staining 
method of Vindelov and Christensen, 1994. Briefly, confluent cells were plated in DMEM + 
5% FBS at the density of 6x105/60 mm2 dish. Cells were allowed to attach for 5 hours, then 
cell monolayers were rinsed twice with 1xHBSS (5.4 mM KCl, 108 mM NaCl, 0.34 mM 
Na2HPO4 x 7H2O, 4.2 mM NaHCO3, 0.44 mM KH2PO4, pH 7.2) buffer to remove all traces 
of the medium and 5 ml of fresh phenol red free PRF-DMEM containing 2% of the 
charcoal/dextran treated FBS (2% stripped serum) was added. The medium was changed two 
more times 20 and 30 hours later to facilitate removal of the endogenous estrogens present in 
the cells. The total incubation period of the cells in the 2% stripped medium was 40 hours, 
similar to the conditions described in the literature (Dubik, D. and Shiu, P., 1992). Finally, at 
the end of the 40 hours, fresh 2% stripped medium +/- drugs was added to the cells. At the 
end of the treatment, for each sample, cell medium was collected in a 15 ml conical tube. 
Cells were harvested by trypsinization, placed into the same tube and counted by 
hemocytometer. For each sample, 5x105 cells were pelleted, washed with 1x HBSS, pelleted 
again, and resuspended in 250 µl of lysis buffer (3.4 mM trisodium citrate dihydrate, 0.1% 
Nonidet P-40, 1.5 mM spermine-4HCl, 0.5 mM Tris base, 0.03 mg/ml trypsin, and 34 µM 
EDTA).  Cells were incubated for 25 min at 37 °C, then 500 µl of trypsin inhibitor/RNAse 
solution (3.4 mM trisodium citrate dihydrate, 0.1% Nonidet P-40, 1.5 mM spermine-4HCl, 
0.5 mM Tris base, 0.5 mg/ml trypsin inhibitor, 0.1mg/ml ribonuclease A) was added for 15 
min at 37 °C. Finally, 500 µl of propidium iodide solution (3.4 mM trisodium citrate 
dihydrate, 0.1% Nonidet P-40, 4.8 mM spermine-4HCl, 0.5 mM Tris base, 74.8 µM 
propidium iodide) was added and cells were incubated at 37 °C for 10 min. Samples were 
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kept on ice up to 24 hours. Flow cytometric analysis of cell cycle distribution was done on 
FACScan (Becton Dickinson, San Jose, CA) using CellFIT software.  
 
2.3.  Western blots 
Cells were rinsed with 1x PBS (phosphate buffered saline: 137 mM NaCl, 2.7 mM 
KCl, 4.3 mM Na2HPO4 x 7H2O, 1.4 mM KH2PO4, pH 7.3) and harvested by scraping in a 
boiling Western lysis buffer (1% SDS, 10 mM Tris, pH 7.4). Cells lysates were transferred 
by 1cc syringe into 1.5 ml tubes, passed through the syringe three times, and boiled for 5 
min. Supernatants were collected by spinning samples at maximal speed for 5 min in 
microcentrifuge at 4°C. Twenty µl aliquots were removed for determination of protein 
concentrations by BCA assay (bicinchoninic acid, Pierce, Rochford, IL) according to the 
manufacturer’s protocol. Dithiothreitol (DTT) and protease inhibitors were added to the final 
concentrations indicated: DTT (1mM), PMSF (phenylmethylsulfonyl fluoride, 0.1 mM), 
aprotinin (1 µg/ml), and leupeptin (1 µg/ml). Extracts containing 60-90 µg of proteins were 
diluted 4:1 with 5x Western sample buffer (3.125 ml of 1M Tris-HCl, pH 7.0, 5 ml Glycerol, 
1 g SDS, 100 µl of saturated Bromophenol Blue solution, q.s. 10 ml with water; 12.5 µl of 2-
Mercaptoethanol/100 µl was added to the 5x buffer fresh each time). Proteins were denatured 
by heating at 100 °C for 3 minutes immediately prior to loading onto 10 % polyacrylamide 
gels. Proteins were separated and transferred to PVDF (polyvinylidene difluoride) 
membranes (NOVEX, San Diego, CA) To reduce non-specific binding of antibodies, 
membranes were incubated in Western blocking buffer (3% non-fat dry milk in Tris-buffered 
saline-Tween 20 (TBST): 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.05% (v/v) Tween 20) 
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overnight at 4 °C. On the next day, membranes were washed 3 times (5 minutes each wash) 
with Western washing buffer (0.1% non-fat milk, 0.1% chick ovalbumin, 1% FBS, 0.2% 
(v/v) Tween 20 in PBS, pH 7.3). All washes were performed at room temperature using an 
Orbital shaker (Bellco Glass, Inc., Vineland, New Jersey). After the washing, membranes 
were incubated inside the Kapak heat sealable pouches (Kapak Corporation, Minneapolis, 
MN) for 3.5 hours at room temperature on a rocker with primary antibody diluted in washing 
buffer. At the end of the incubation, membranes were washed 3 times (5 minutes each) with 
Western washing buffer and once with TBST buffer. The membranes then were incubated for 
40 min on a rocker at room temperature with peroxidase-conjugated secondary antibodies 
diluted in TBST. After that, membranes were washed 3 times (10 minutes each wash) with 
TBST. The specific protein signals (Myc or β-catenin) were visualized using 
chemiluminescent peroxidase substrate (Super Signal, Pierce, Rockford, IL) for 7 minutes 
and exposing the membranes to the Kodak X-OMAT film (Eastman Kodak Co., Rochester, 
NY). Autoradiographic signals were quantified by densitomery (Personal Densitometer SI, 
Molecular Dynamics, Sunnyvale, CA) and Image QuaNT software, version 4.1. Myc signals 
were normalized to the 97 kDa β-catenin protein signals.  
 
2.4.  Northern blots 
Total cellular RNA was purified by the method of Chomczynski and Sacchi 
(Chomczynski, P. and Sacchi, N., 1987). Briefly, cells were harvested by scraping in 
2.5ml/T-75 flask of ice-cold RNA harvesting buffer (4M guanidinium thiocyanate, 25mM 
sodium citrate, pH 7.0, 0.1M 2-mercaptoethanol, 0.5% N-laurylsarcosine) and transferred 
into pre-cooled sterile 15ml conical tubes. All of the following steps were performed on ice. 
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Cellular DNA was sheared by passing the cell lysates through a 22 gauge needle with a 5ml 
syringe. Two hundred and fifty µl of 2M sodium acetate, pH 4.0, 2.5 ml of water-saturated 
phenol, and 1ml of chloroform were added and mixed thoroughly by shaking. The lysates 
were incubated on ice for 30 minutes and centrifuged in a Sorvall H-1000B rotor at 3,500 
rpm for 15 min at 4 °C. The upper aqueous phase containing the RNA was carefully 
transferred into a clean 15ml conical tube. The white interphase containing proteins and 
DNA should be avoided. RNA was then precipitated by adding 2.5ml volumes of  
isopropanol and incubating at -20°C overnight. Precipitated RNA was collected by 
centrifuging for 30 min in a Sorvall H-1000B rotor at 3,500 rpm at 4 °C. The supernatant was 
discarded; the RNA pellet was resuspended in ice-cold 75 % ethanol, and transferred to a 
clean Eppendorf tube. The RNA solution was spun in an Eppendorf microcentrifuge at 
maximal speed for 10 minutes at 4 °C. The supernatant was removed and the RNA pellet was 
dissolved in an appropriate amount of DEPC (diethyl pyrocarbonate) -treated water. Two µl 
of RNA from each sample was dissolved in 998 µl (1:500 dilution) of the DEPC water and 
their absorbency at 260 nm was measured using a spectrophotometer (DMS 80 Varian, 
Australia). To quantify RNA concentration (in µg/µl), the optical density reading was 
divided by 24 and multiplied by 500 (the dilution factor). Fifteen µg of RNA for each sample 
was mixed with 5x RNA sample buffer (0.75 ml deionized formamide, 0.15 ml 10x MOPS 
(3-[N-morpholino] propanesulfonic acid), 0.24 ml 37 % formaldehyde, 0.14 ml RNase-free 
water, 0.1 ml glycerol, 0.04 ml 10 % bromophenol blue) at a ratio of 4:1. RNA was separated 
on 1.2% agarose-1.9 % formaldehyde gels in MOPS running buffer (20 mM MOPS, 5 mM 
sodium acetate, 0.5 mM EDTA, pH 8.0), and transferred to 0.2 mm nitrocellulose paper 
(Schleicher and Schuell, Keene, NH) by capillary action. Membranes were air-dried for 5 
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minutes and baked in a vacuum oven at 80 °C for 2 hours to fix the RNA. After that, the 
membranes were incubated in the pre-hybridization solution (50% formamide, 250 mM 
NaHPO4, pH 7.2, 250 mM NaCl, 1 mM EDTA, pH 8.0, 1mg/ml of denatured salmon sperm 
DNA, 7% SDS) in the Micro-hybridization oven (Bellco Glass Inc., Vineland, NJ) at 42 °C 
for 15-20 hours to decrease non-specific binding of the probe. Next, the pre-hybridization 
solution was exchanged with the hybridization solution (the same pre-hybridization solution 
plus denatured c-myc DNA fragment labeled with [αP32]dCTP by random priming 
(Rediprime DNA labeling kit, Amersham Corp., Arlington Hts., IL). About 1.5-2 x 106 cpm 
of the probe/ml of the hybridization mix was used. Hybridization reactions were performed at 
42°C for 40-42 hours, then blots were washed in 2x SSC (Standart Saline Citrate)-0.1% SDS 
solution twice for 20 minutes each wash at 37°C. A high stringency wash of the c-myc probe 
was performed for 15 minutes at 42°C in 0.1x SSC-0.1% SDS buffer. Blots were exposed in 
a phosphorimager cassette. Quantitative analysis of the hybridization signals was performed 
using PSI-PC (Molecular Dynamics, Sunnyvale, CA) and ImageQuaNT software, version 
4.1. Hybridization signals were normalized to levels of 18S or 28S RNA in the ethidium 
bromide stained gels. 
 
2.5.  Reporter gene assay 
Transient transfection procedure.  All plasmids used in the reporter gene assay were 
purified using Qiagen DNA purification columns, according to the manufacturer’s protocols. 
On day one, confluent MCF-7 cells were re-plated at the density of 8x105/60 mm2 tissue 
culture dish in 5 ml DMEM/5%FBS medium. After 20-24 hours, when cells reached about 
40-50 % confluency, cell monolayers were rinsed with 1xHBSS (Hank's Balanced Salt 
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Solution) buffer and 5ml of DMEM/2%FBS medium were added. One hour later, 
transfections were started by adding the transfection mixes to the cells. The transfection 
mixes were prepared in a sterile 3ml glass tubes by mixing 5 µg of plasmid DNA, 30 µl of 
the DOTAP liposomal transfection reagent (1811177, Roche Molecular Biochemicals), and 
water to the final volume of 150 µl for each sample. This volume was calculated to carry out 
transfections in 60 mm2 dishes, in 5ml medium. Transfection mixes were incubated at room 
temperature for 15 minutes. Transfections were terminated 6-7 hours later by exchanging the 
medium with fresh medium +/- drugs. 
Luciferase Assay. Cells were harvested 24 hours after the end of transfections by 
scraping into ice-cold lysis buffer (25 mM Tris-phosphate, pH 7.8, 1% Triton X-100, 2mM 
EDTA, 10% Glycerol). All the following steps were performed on ice. Cell lysates were 
transferred into 1.5 ml Eppendorf tubes and spun in the Eppendorf microcentrifuge at 
maximal speed for 5 minutes at 4°C. The supernatants were transferred into clean tubes. 
Aliquots of 20 µl were removed for determination of protein concentrations by BCA assay. 
To measure luciferase activity, 50 µl of cell extracts were added to 250 µl of ice-cold 
luciferase sample buffer (25 mM glycylglycyl, pH 7.8, 15 mM MgSO4) in 12x75 mm 
polypropylene culture tubes (60818-430, VWR Scientific, West Chester, PA). Immediately 
before measuring the luciferase activity, the samples were warmed to 25 °C (the optimal 
temperature for luciferase enzymatic activity). Luciferase activity was measured using an 
Auto Luminat (LB 953, EG and G-Bertholdt) equipped with a dual injection system. The 
reactions were initiated by automatic injections of 100 µl of ATP solution (25 mM 
glycylglycyl, pH 7.8, 15 mM MgSO4, 20 mM ATP) and 100 µl of the luciferin solution (25 
mM glycylglycyl, pH 7.8, 1 mM luciferin) into each sample. The production of the light was 
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measured. The following luminometer settings were used: incubation temperature =25 °C, 
reading time =6 seconds, injection amount =100µl. The ATP solution was placed in the 
measuring position 1, and the luciferin solution was placed in the measuring position of the 
luminometer. The relative luciferase units obtained from 50 µl of cell extracts were 
normalized to 200 µg of cellular proteins. Light generation from purified luciferase (Sigma) 
was used as the standard in each experiment to ensure that all determinations were performed 
under linear assay conditions. The amount of sample buffer, lysis buffer, and purified 
luciferase used for the standard curve are given in the Table below. 
 
Sample buffer (µl) Lysis buffer (µl) 5 pg/µl luciferase solution (µL) 
250 50 0 
248 50 2 (10 pg) 
246 50 4 (20 pg) 
242 50 8 (40 pg) 
234 50 16 (80 pg) 




2.6.  Ki-67 immunohistochemistry. 
MCF-7 cells were plated at the density of 2x105/ 35 mm2 tissue culture dish on sterile 
glass cover slips in 3 ml of DMEM/5%FBS +/- drugs. At the end of the treatment, the 
medium was removed by aspiration and cells were fixed by transferring the cover slips to a    
- 20°C fixing solution (50% acetone/50% ethanol) for 10 minutes on ice. All the following 
steps were performed at room temperature. Cells were rinsed with the working PBS (wPBS) 
solution (1x PBS, 0.15 % bovine serum albumin), and freshly made Blocking solution #1 
(1:100 dilution of 30% H2O2 in methanol) was added to the cells for 15 minutes to block 
endogenous peroxidase activity. Cells were rinsed with wPBS, and then Blocking solution #2 
(10% horse serum in wPBS) was added for 30 minutes to block non-specific binding of 
antibodies. The blocking solution was carefully removed, leaving a thin layer of it on the 
cover slips, and 500 µl/cover slip of diluted Ki-67 antibody (1:50 ratio in wPBS) were added 
for one hour. Cells used for the negative control remained in the blocking solution #2. Ki-67 
antibody was removed by rinsing cells with wPBS for 5 minutes and biotinylated anti-mouse 
IgG secondary antibody (1:125 dilution in wPBS) was added for 30 minutes. The Biotin-
Avidin solution (B/A) was prepared 30 minutes prior to use by adding 1 drop of each 
Reagent A and B (PK-6100, Peroxidase Vectastatin Elite ABC kit, Vector Laboratories, 
Inc.). The secondary antibody was removed by rinsing cells with wPBS for 5 minutes and 
B/A solution was added for 30 minutes. After that, cells were rinsed with wPBS for 5 
minutes and a peroxidase substrate, DAB (750118, Research Genetics, Inc.) was added for 
10 minutes. Cells were rinsed with wPBS and counterstained with Mayer’s hematoxylin 
(Sigma) for 1-2 minutes to visualize cell nuclei. Cover slips were mounted with Permount 
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solution (SP15-100, Fisher Scientific). The images were obtained using an Ortholux 
microscope (Ernst Leitz Wetzlar, Germany) (40x objective). Cells were scored using Image-
Pro Plus software (Media Cybenetics, Silver Spring, MD). 
 
2.7.  Oil-Red O assay 
Cells were plated in 35 mm2 tissue culture dishes on sterile glass cover slips in 
DMEM/5%FBS +/- drugs. At the end of the treatment, the cover slips were transferred into 
60 mm2 glass dishes containing 3 ml of cell fixative solution (10% formaldehyde and 0.2% 
calcium acetate in PBS) for 3 minutes. The fixative was removed by aspiration and 3 ml of 
freshly made Oil-Red O working solution (Oil-Red O stock solution [0.5 % Oil-Red O in 
98% Isopropanol] diluted in water in a 3:2 ratio) were added for 10 minutes. Cells were then 
rinsed in water and counterstained with Mayer’s hematoxylin solution (Fisher, Pittsburgh, 
PA) for 1 min at room temperature. Cells were briefly washed in 0.4 % NH4OH, rinsed in 
distilled water, and then mounted with 50% glycerol solution (a filtered 1:1 dilution of 
Glycerol in water). The images were obtained using Ortholux microscope (Ernst Leitz 
Wetzlar, Germany) (40x objective). Cells were scored using Image-Pro Plus software (Media 
Cybenetics, Silver Spring, MD). 
 
2.8.   Nile Red staining 
Cells were plated at the density of 1x105/ 35 mm2 dishes on sterile glass cover slips 
and grown for 96 hours in DMEM/5%FBS +/- drugs. At the end of the treatment, cells were 
fixed in 3.7% formaldehyde/PBS, rinsed in PBS, and then treated briefly with 0.4% Triton X-
100 in PBS. After rinsing 3 times in PBS, the cells on cover slips were incubated with 
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fluorescein-phalloidin antibody (1:200 dilution of a 5µg/0.1 ml solution, Sigma) in the dark 
for 40 minutes at room temperature. Cells were then rinsed with PBS and incubated for 5 
minutes with the fluorescent lipid stain, Nile Red (1:10,000 dilution of a 1mg/ml acetone 
solution, Sigma) (Greenspan, P. et al, 1985; Toscani, A. et al, 1990). The cover slips were 
rinsed with PBS and mounted with Fluoromount-G containing 2.5% N-propyl galate to 
minimize photobleaching. Images were obtained using a Zeiss Axiovert 100M confocal 
microscope (63x objective). 
 
2.9.   MTS assay 
Cells were plated in a 96-well dishes in DMEM/5%FBS +/- drugs at the following 
densities, depending upon the relative growth rates of the cell lines: HMEC (2000), MCF-7 
(1000), MDA-231 (500), T47D (1500). At the end of the treatment time, the medium was 
removed by aspiration. One hundred µl of DMEM/5%FBS and 20 µl of the MTS reagent 
(CellTiter 96 AQueous one solution cell proliferation assay, Promega Cor., Madison, WI) 
were added to each well using a multichannel pipetteman. The plated cells were incubated 
for 2 hours at 37 °C. Absorbency readings were obtained at a wavelength of 490 nm with a 
microplate spectrophotometer (Molecular Devices). 
 
2.10.  Statistics 
The SigmaPlot software (SPSS Inc., Chicago, IL), version 5.0 and JMP software 
(SAS Institute, Inc., Cary, NC) were used for statistical analysis. One way analysis of 
variance (ANOVA) followed by the Dunnett’s test for comparison of multiple groups with 
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control or the Turkey-Kramer test for comparison between the different groups was used. A 




1. Quinidine Reduces Myc Protein Levels in Human Breast Cancer Cells 
1.1.   Rapid suppression of Myc protein levels by quinidine in MCF-7 cells 
Transient induction of c-myc mRNA and protein levels is a prerequisite for G0-G1 
and G1 phase transition. According to our hypothesis, rapid suppression of Myc by quinidine 
causes cell cycle arrest at the D point in the early G1 phase of the cell cycle due to the lack of 
Myc-dependent transcription of the genes required for cells to pass through the D point. The 
purpose of this experiment was to test how rapidly quinidine suppresses Myc protein. 
MCF-7 cells were grown in T-75 tissue culture flasks until 95-100 % confluency (1.5-2 
x 107 cells/T-75) in order to obtain a population of cells largely (85%) in G0/G1 phase 
(Wang, S., et al, 1998). Before plating, the viability of the cells was assayed using a 
hemocytometer to obtain cell counts and trypan blue dye to detect the dead cells. The 
viability ranged from 96 to 100 %. The synchronized cells were then plated at the density of 
3.5 x 106 viable cells per 100 mm2 tissue culture dish in 10 ml of DMEM/5% FBS medium. 
90 µM quinidine or H2O (vehicle) was added to the dishes. One dish of each, control and 
quinidine-treated cells was harvested in protein harvesting buffer 0, 60, 90, 120, 180 min 
after the plating. Equal amounts of proteins (60 to 90 µg depending on the experiment) were 
loaded into each well of 10 % polyacrylamide gels. As shown in Figure 6, a transient 
increase in Myc protein levels occurs after sub-cultivating confluent MCF-7 cells in fresh 
medium (release from the high cell density condition). The maximal increase in Myc protein 
levels was 15-fold, achieved at 90 min after plating. This rise in Myc protein was suppressed 
by quinidine, with the maximal level of suppression (60%) achieved at 60 min. The data 
indicate that suppression of Myc protein levels occurs rapidly, and precedes the quinidine-
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induced cell cycle arrest (see Figure 3). This observation is a critical evidence in support to 
our hypothesis that quinidine acts on Myc early in the G1 phase of the cell cycle, prior to cell 
cycle arrest. Therefore, suppression of Myc protein by quinidine is not simply a result of cell 
cycle arrest, but, in contrary, may play a causative role in it. 
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Figure 6.  Quinidine suppresses Myc protein levels in MCF-7 cells. 
 
Confluent (Cf) MCF-7 cells were sub-cultivated at 0 time in DMEM/5%FBS (solid bars) or 
in DMEM/5%FBS containing 90 µM quinidine (hatched bars). Cells were harvested for 
Western blot analysis at the times indicated. Myc protein signals were quantified by 
densitometry and normalized to the β-catenin signals. Data shown in the bar graph are the 
mean Myc protein signals +/- S.D. of n =3 experiments expressed as a percent of maximal 
stimulation (at 1.5 hours). The differences between the percentages of control and quinidine-
treated cells were statistically significant (p<0.05) at 1 and 1.5 hours. The gel scans below the 




1.2.  Suppression of Myc by quinidine in MCF-7 cells is not mediated by the 
impediment of cell attachment. 
Some cell lines growing in tissue culture (epithelial cells, fibroblasts) require their 
attachment to the special surface for the proper cell cycling, while others (lymphocytes) can 
grow in a suspension. Therefore, any condition, that affects attachment of cells to the growth 
surface can influence cell progression through the cell cycle. In the experiment described 
above, quinidine was added to the cells immediately after the plating. At this point most of 
the cells were loosely attached to the tissue culture dishes. The purpose of current experiment 
was to test the influence of quinidine on the attachment of MCF-7 cells. If quinidine impedes 
cell attachment, then suppression of Myc by quinidine and subsequent cell cycle arrest could 
be simply the results of quinidine’s effect on cell attachment.  
Confluent MCF-7 cells were re-plated in 60 mm2 tissue culture dishes in 5 ml DMEM-
5% FBS at the density of 0.8x106 cells/dish. Cells were allowed to attach for 3 hours. Then, 
the medium was changed to DMEM-2% FBS and 72 hours later cells were treated with: 1) 
DMEM-2% FBS, 2) DMEM-5% FBS, 3) DMEM-5% FBS + 90 uM quinidine. Cells were 
harvested 1 hour later. Seventy µg of proteins were loaded into each well of 10 % 
polyacrylamide gels and Western blot assay was performed as described in the Materials and 
Methods. As shown in Figure 7, MCF-7 cells growing in DMEM-2% FBS (low serum 
condition) have very low Myc protein levels. Addition of DMEM-5% FBS to these cells 
caused rapid (within 1 hour) induction of Myc protein. Ninety µM quinidine completely 
abolished this effect. These results demonstrate that quinidine suppresses Myc protein levels 
to the same extent in both attached (down to 36%, Figure 7) and loosely attached (down to 
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38%, Figure 8) MCF-7 cells, suggesting that suppression of Myc by quinidine is not 




Figure 7. Suppression of Myc by quinidine in MCF-7 cells is not mediated by the 
impediment of cell attachment. 
 
Confluent MCF-7 cells were sub-cultivated in DMEM-5% FBS, allowed to attach for 3 hours 
and then incubated in DMEM-2% FBS (low serum conditions) for 72 hours. After that, cells 
were treated for 1 hour with: DMEM-2% FBS (2%), DMEM-5% FBS (5%), or DMEM-5% 
FBS + 90 uM quinidine (Qd). Myc protein levels after Western blot assay were determined 
by densitometry and normalized to the β-catenin levels. Myc protein levels in DMEM-5% 
FBS treated cells were set to 100%. The numbers above the bars show Myc levels in 
DMEM-2% FBS and DMEM-5% FBS+Qnd treated cells relative to DMEM-5% FBS treated 
cells. The bar graph data are the mean +/- S.D. of n=2 experiments performed in duplicates. 
The gel scans below the bar graph are a single representative experiment. 
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 1.3. Rapid suppression of Myc protein in other breast cancer cell lines 
The purpose of this experiment was to assay whether the rapid decrease of Myc 
protein by quinidine is specific to MCF-7 cells or is more general response of breast tumor 
cells to quinidine. Three other cell lines used in this experiment were: MCF-7ras, MDA-MB-
231, and MDA-MB-435. MCF-7ras cells have high, constitutive expression of Myc protein 
due to the activated ras-MAP kinase pathway. MDA-MB-231 and MDA-MB-435 cells are 
ERα-/ERβ+ and ERα-/ERβ-, respectively (Vladusic, E., et al, 2000). These two cell lines 
were chosen to assay if the ER status influences the Myc response to quinidine. Confluent 
cultures of the cells were re-plated in 100 mm2 dishes in 10 ml DMEM-5 %FBS at the 
density of 3x106 cells/dish and treated with 90 µM quinidine or H2O (vehicle). Cells were 
harvested one (MCF-7ras, MDA-MB-231, MCF-7) or two (MDA-MB-231, MDA-MB-435) 
hours later. The two-hour time point for MDA-MB-435 and MDA-MB-231 cells was chosen, 
because in these cell lines the maximum levels of Myc protein after the release of cells from 
high density are reached at this time. Equal amounts of proteins (70 µg) were loaded into 
each well of 10 % polyacrylamide gels. As demonstrated in Figure 7, quinidine suppressed 
Myc protein levels by 82% (MCF-7ras), 65% (MDA-231), 62% (MCF-7), and 59% (MDA-
435) in these cell lines. The variance in control Myc levels of different cell lines (Figure 7 gel 
scan) is in a good correlation with their proliferative rate (see Figure 18), which underlines 
the role of Myc in cell proliferation. These results show that rapid decrease in Myc protein 
levels by quinidine occurs in all four human breast cancer cell lines tested and is independent 






Figure 8. Quinidine suppresses Myc protein in MCF-7ras, MDA-231, and MDA-435 
cells. 
 
Confluent MCF-7, MCF-7ras, MDA-231, and MDA-435 cells were sub-cultivated in 
DMEM/5%FBS +/- 90 µM quinidine. Cells were harvested at indicated time points and Myc 
protein levels after Western blot assay were determined by densitometry in control (solid 
bars) or quinidine-treated (hatched bars) cells. Myc signals were normalized to the β-catenin 
signals. Myc protein levels in quinidine-treated cells expressed as a percent of the respective 
controls for each cell line are shown above the hatched bars. The bar graph data are the mean 
+/- S.D. of n =3 experiments with MCF-7 and MCF-7ras cells, and the mean +/- range in n 
=2 experiments with MDA-231 and MDA-435 cells. The gel scans below the bar graph are a 
single representative experiment performed with 70 µg of cell extract protein/lane. 
∗  Significantly different from control values (p<0.05). 
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1.4.  Suppression of Myc protein by quinidine is sustained within 24-hour tested period 
The objective of this experiment was to determine the character of Myc suppression 
by quinidine: transient versus sustained. MCF-7 and MCF-7ras cells were re-plated from 
confluent T-75 flasks at the density of 3 x 106 cells/100 mm2 tissue culture dish in 10 ml 
DMEM/5%FBS medium. Zero, 30, or 90 µM quinidine was added to the cells. Twenty-four 
hours later cells were harvested and 70 µg of proteins for each sample were separated on 
10% polyacrylamide gels. As shown in Figure 9, quinidine caused concentration-dependent 
reductions in the levels of Myc protein in both cell lines after 24 hours of treatment. Thirty 
µM quinidine caused a more than a 50 % reduction in Myc protein levels in both cells, 
compared with respective untreated control cells. Ninety µM quinidine further reduced Myc 
protein levels by 88 % and 68 % in MCF-7ras and MCF-7 cells, respectively. The high levels 
of Myc protein in the control MCF-7ras cells compared to MCF-7 cells are due to the 
constitutive expression of the Myc in MCF-7ras cell line. In MCF-7 cells Myc is transiently  
induced during the G0-G1 and G1 phase transition (Figure 6) and then stays at constant low 




Figure 9. Suppression of Myc protein by quinidine. 
 
Confluent MCF-7 and MCF-7ras cells were sub-cultivated in DMEM/5%FBS +/- different 
concentrations of quinidine. Cells were harvested 24 hours later and Myc protein levels after 
Western blot assay were determined by densitometry. Myc signals were normalized to the β-
catenin signals. The bar graph shows Myc protein levels in MCF-7 (solid bars) and MCF-
7ras cells (hatched bars) as the mean +/- S.D. of n =4 (MCF-7) and n=3 (MCF-7ras) 
experiments. The numbers above the bars indicate the average Myc signal (% of control). 
The gel scans below the bar graph are a single representative experiment performed with 70 
µg of cell extract protein/lane. 
∗  Significantly different from control values (p<0.05) 
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1.5. Quinidine does not affect Myc protein levels in normal mammary epithelial cell line 
MCF10A. 
The abnormal expression of c-myc was reported in 32% of breast cancers, suggesting 
its importance in the genesis and/or progression of breast cancer. Hence, our findings that 
quinidine inhibits Myc protein levels in four different breast cancer cell lines by 60-80% are 
very promising.  The goal of this experiment was to test the effect of quinidine on Myc 
protein in MCF10A normal mammary epithelial cell line.  
MCF10A cells were re-plated from confluent T-75 flasks at the density of 6 x 105 
cells/60 mm2 tissue culture dish in 5 ml MEGM medium +/- 90 µM quinidine. Twenty-four 
hours later, cells were harvested and 60 or 70 µg of proteins for each sample were separated 
on 10% polyacrylamide gels. As shown in Figure 10, quinidine didn’t cause a significant 
reduction in Myc protein levels in this cell line. As has been discussed earlier, one of the 
major problems with current chemotherapeutic drugs for breast cancer treatment is their lack 
of selectivity for tumor tissue and associated with it toxicity in normal tissues. That why, it is 
important to show, that quinidine selectively inhibits Myc protein in breast cancer but not in 
normal breast epithelial cell lines.  
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Figure 10. Quinidine does not affect Myc protein levels in MCF10A normal mammary 
epithelial cells. 
      
Confluent MCF10A cells were sub-cultivated in MEGM +/- 90 uM quinidine. Cells were 
harvested 24 hours later and Myc protein levels after Western blot assay were determined by 
densitometry. Myc signals were normalized to the β-catenin signals. The bar graph shows 
Myc protein levels in control (solid bars) and quinidine-treated (hatched bars) cells as the 
mean +/- S.D. of n=3 experiments. The numbers below the gel scans indicate the Myc 
protein levels in two 2 independent experiments. 
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2.   Quinidine Reduces c-myc mRNA Levels in Breast Cancer Cells. 
2.1.  Suppression of c-myc mRNA levels by quinidine in MCF-7 and MCF-7ras cells. 
MCF-7 and MCF-7ras cells were re-plated from the confluent state into the T-75 
tissue culture flasks at the density of 3.5 x 106/flask in 10 ml of DMEM/5%FBS. Cells were 
treated with 0, 30, and 90 µM quinidine. Twenty-four hours later, total cellular RNA was 
purified, separated on 1.2% agarose-1.9% formaldehyde gels, transferred to nitrocellulose 
paper, and hybridized to the radiolabeled c-myc probe, as described in the Materials and 
Methods.  Fifteen µg of total RNA were loaded into each well. Quantitative analysis of the 
specific c-myc hybridization signals was performed using a PSI-PC (Molecular Dynamics, 
Sunnyvale, CA) and ImageQuaNT software, version 4.1. The c-myc mRNA signals were 
normalized to 18S ribosomal RNA signals on the ethidium bromide stained gel. The results 
are shown in Figure 11. Quinidine caused a concentration-dependent suppression of c-myc 
mRNA levels in both cell lines. Thirty µM quinidine reduced c-myc mRNA levels by 53% 
and 31% in MCF-7 and MCF-7ras cells, respectively. Ninety µM quinidine further reduced 
c-myc mRNA levels by 78% in MCF-7 and 63% in MCF-7ras cells. These results suggest 
that the quinidine-induced changes in Myc protein levels observed at 24 hours (Figure 9) 




Figure 11. Suppression of c-myc mRNA by quinidine.  
 
Northern blots were performed using 15 µg of total cell RNA/lane isolated from MCF-7 
(solid bars) and MCF-7ras (hatched bars) cells 24 hours following sub-cultivating of 
confluent monolayers +/- 30 or 90 µM quinidine. The numbers above each bar represent c-
myc mRNA levels in quinidine-treated cells as a percent of control. The c-myc mRNA P32 
hybridization signals and the 18S ribosomal RNA signals from ethidium bromide stained gels 




2.2.   Suppression of estradiol-induced c-myc mRNA levels and cell cycle progression by 
quinidine in MCF-7 cells. 
Estrogen plays an important role in etiology of breast cancer. About 30-40% of human 
breast tumors are dependent on estrogen for growth in initial state of the disease (van der 
Burg et al., 1992). Stimulation of c-myc gene by estradiol in estrogen-dependent MCF-7 cells 
is critical to initiate progression of cells through G1 phase of the cell cycle and to activate 
cell proliferation (Prall, O. et al, 1998). c-myc mRNA is rapidly (within 1 hour) induced by 2 
nM estradiol in MCF-7 cells (Dubik, D. and Shiu, R., 1988). 
The objective of this experiment was to test if quinidine can suppress estradiol-induced 
c-myc mRNA levels and cell cycle progression. MCF-7 cells were re-plated from the 
confluent state into the T-75 tissue culture flasks at the density of 2.6x106/flask in 10 ml of 
DMEM-5% FBS (for Northern blots) or into 60 mm2 tissue culture dishes at the density of 
6x105/dish in 5 ml of DMEM-5% FBS (for flow cytometry). Cells were allowed to attach for 
5 hours, then cell monolayers were rinsed twice with 1xHBSS buffer to remove all traces of 
the medium and 10 ml (per T-75) or 5 ml (per 60 mm2 dish) of fresh phenol red free (PRF) -
DMEM containing 2% of the charcoal/dextran treated FBS (2% stripped serum) was added. 
The medium was changed two more times 20 and 30 hours later to remove the endogenous 
estrogens present in the cells. The total incubation period of the cells in the 2% stripped 
medium was 40 hours, similar to the conditions described in literature (Dubik,D. and Shiu, 
P., 1992). Finally, at the end of the 40 hours, fresh 2% stripped medium +/- drugs was added 
to the cells. Control cells (C) received 0.01% ETOH (vehicle), estradiol-treated cells (E2) 
received 2 nM estradiol, and cells treated with both estradiol and quinidine (Q+E2) received 
2 nM estradiol + different concentrations of quinidine.  
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For Northern blot total cellular RNA was isolated 1 hour after addition of the drugs. 
Fifteen µg of RNA was loaded into each well and separated on 1.2% agarose-5.4% 
formaldehyde gels. The RNA transfer to nitrocellulose paper, hybridization procedure, and 
quantification of c-myc mRNA signals was performed as described in the experiment 2.1. As 
shown in the Figure 12, quinidine caused rapid concentration-dependent suppression of 
estradiol-induced c-myc mRNA levels in MCF-7 cells, with the maximum inhibition by 60% 
achieved with 90 µM quinidine. 
For cell cycle analysis cells were harvested 30 hours after addition of the drugs. Cell 
nuclei were stained with propidium iodide and flow cytometry was performed as described in 
Materials and Methods. The results are shown in Figure 13. Most (80%) of the control cells 
were in G1/G0 phase of the cell cycle due to the low (2% stripped FBS) serum condition. 
Only 11% of the control cells progressed into the S phase. Two nM estradiol caused a 
significant increase in S phase cells (34 % of total) with a concomitant decrease in G1/G0 
phase cell population (49% of total). Quinidine significantly (by 59%) suppressed estradiol-
stimulated S phase progression. Seventy-five percent of Q+E2 cells were arrested in G1/G0, 
and only 14% reached S phase.  
In summary, these results show that quinidine inhibits both estradiol-stimulated c-myc 
mRNA levels and G1 to S phase progression in MCF-7 cells. There was a good correlation 
between decreases in c-myc mRNA (60%) and S phase cells (59%) by quinidine, suggesting 




Figure 12. Suppression of estradiol-stimulated c-myc mRNA by quinidine. 
 
Confluent MCF-7 cells were sub-cultivated in PRF-DMEM/2% stripped serum, and 
estrogen-depleted by replacing this medium twice during the total of 40 hours time period. 
Induction of c-myc mRNA by 2 nM estradiol +/- different concentrations of quinidine was 
measured after 1 hour by isolating total cell RNA and Northern blotting. Myc mRNA signals 
were normalized to the 28S ribosomal signal in the ethidium bromide stained gel. Data 
shown on the bar graph are the mean +/- S.D. of n = 3, except for 30 and 50 µM quinidine 
that are from a single experiment. Values for E2 and E2+Qnd treated groups are reported 
relative to control group (control=1). The differences between the percentages of estradiol- 





Figure 13. Suppression of estradiol-stimulated S phase progression by quinidine. 
 
Confluent MCF-7 cells were sub-cultivated in PRF-DMEM/2% stripped serum, and 
estrogen-depleted by replacing this medium twice during the total of 40 hours time period. 
Cells were treated with Ctr-0.01% ETOH (vehicle), Qnd- 90 µM quinidine, E2- 2nM 
estradiol, Qnd+E2- 90 µM quinidine + 2nM E2. Cell cycle phase distribution was analyzed by 
flow cytometry 30 hours later. Data shown on the bar graph are mean +/- S.D. of n = 4 
experiments.  
∗  Significantly different from control cells (p<0.05) 
# Significantly different from E2 cells (p<0.05) 
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3. Quinidine Inhibits c-myc Promoter Activity. 
3.1.  Quinidine inhibits c-myc promoter activity in MCF-7 cells 
To determine whether the suppression of c-myc mRNA levels is mediated by effects of 
quinidine on the activity of c-myc promoter, transient transfection assays were performed in 
MCF-7 cells using a myc-luciferase plasmid. The construct containing 2.8 kb human c-myc 
promoter linked to the luciferase reporter gene (Del-1) was kindly provided by Dr. Bert 
Vogelstein, Johns Hopkins University. MCF-7 cells were plated in 5 ml DMEM/5%FBS at 
the density of 8 x105 cells per 60 mm2 tissue culture dish. Seventeen hours later, the medium 
was replaced with PRF-DMEM/2% stripped FBS medium and, one hour later, transfections 
were started using DOTAP transfection reagent and 5 µg of plasmid DNA according to the 
procedure described in the Materials and Methods. Transfections were terminated in 6-7 
hours by replacing the medium with fresh DMEM/5%FBS +/- different concentrations of 
quinidine. Cells were harvested 24 hours later, when the maximal levels of myc-driven 
luciferase activity occurred. Luciferase activity was measured in cell extracts containing 200 
µg of proteins using an Auto Lumat (LB 953, EG and G-Bertholdt). Luciferase activity in the 
cells transfected with transfection reagent alone or with promoterless construct was always 
less then 0.01% of the activity in the control cells transfected with myc-luc construct. Light 
generation from purified luciferase was used as the standard in each experiment to insure that 
all determinations were performed under linear assay conditions. As demonstrated in 
Figure14, quinidine treatment caused a concentration-dependent decrease in the activity of 
the c-myc promoter. Ninety µM quinidine decreased c-myc promoter activity by 60%. This 
experiment provide an evidence that the activity of c-myc promoter is suppressed over the 
same range of quinidine concentrations that suppress levels of c-myc mRNA and protein.  
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The next goal was to identify the minimal region of the c-myc promoter, a putative 
quinidine responsive element (QRE), which is sufficient to confer quinidine responsiveness 




Figure 14. Quinidine suppresses c-myc promoter activity. 
 
Confluent MCF-7 cells were sub-cultivated, allowed to attach, transferred into PRF-
DMEM/2% stripped serum, and transfected with 5 µg/dish of 2.8 kb human c-myc promoter-
luciferase reporter plasmid or with the transfection mix alone (DOTAP). At the end of 
transfection cells were incubated for 24 hours in DMEM/5%FBS + the indicated 
concentrations of quinidine before preparing cell extracts for luciferase assay. Data shown 
are the mean +/- S.D. of n =3 experiments (90 and 120 µM Qnd) and n=2 experiments (30 
and 50µM Qnd). Luciferase activity was measured in extracts containing 200 µg of protein, 
and the data expressed as a percent of luciferase activity in control cells (100%). Luciferase 
activity in mock-transfected cells (DOTAP) was < 0.01% that of control cells.  




 3.2.  QRE is located within 168 bp region of the c-myc promoter between -100 and +68 
with respect to P1. 
To determine the minimal region of the c-myc promoter that is sufficient for quinidine 
responsiveness, several c-myc promoter 5'-deletion mutants of the original Del-1 construct 
were used. The mutant constructs were kindly provided by Dr. Bert Vogelstein, Johns 
Hopkins University. Their structures are shown in Figure 15. These constructs were 
transiently transfected into MCF-7 cells and their relative luciferase activities in response to 
quinidine were assayed 24 hours later in an identical manner as described in 3.1. The basal 
(control) levels of c-myc promoter activity varied among these mutant constructs (Figure 
15B), presumably due to the presence of different negative and positive regulatory elements. 
For example, the Del-1 has lower levels of basal luciferase activity compared to the Del-2 
and Del-4, due to the presence of the negative repressor binding site in its promoter sequence 
that correlates with DH I (see Table 2) located 1851 bp upstream of the P1. The lower levels 
of basal promoter activity in the Frag-E compared to the Del-2 and Del-4 are explained by 
the deletion of the five tandem CT-boxes (CCCTCCCC) located 101 bp upstream P1. These 
CT-boxes are required to promote transcription from P1 and for maximal activity of P2 (see 
Table 3). In all these deletion constructs quinidine inhibited c-myc promoter activity by 60-
70% (Figure 16A). In contrast, quinidine had a little effect on the promoterless construct 
(Luc, Figure 16B), suggesting that effects of quinidine are specific for c-myc promoter. The 
results from this experiment suggest that the putative QRE is located within 168 bp region of 
the Frag-E construct, since this region was sufficient to confer quinidine responsiveness of 
the c-myc promoter. This region contains two important cis-elements: the TGF β1 control 
element (TCE) and region from -60 to -37 that contains Sp1/Sp3 binding site (see Table 3). 
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The first element is involved in inhibition of c-myc P1 transcription initiation in response to 
TGF β1, whereas the presence of intact second element is essential for P1 transcription. The 
further fine mapping of QRE within the Frag-E using specific PCR primers could help in 
understanding the importance of these binding sites in the quinidine-mediated regulation of 





Figure 15. The structures of the 5’-deletion mutants of the original Del-1 construct.   
    
The gray and white rectangles represent c-myc promoter and luciferase coding region, 
respectively. P1 and P2 are the sites of the transcription initiation from the respective 
promoters. The restriction enzymes and their cut sites are shown above the Del-1 construct. 








Figure 16. Inhibition of c-myc promoter activity in 5'-deletion mutants of the Del-1 by 
quinidine. 
 
Confluent MCF-7 cells were sub-cultivated, allowed to attach, transferred into PRF-
DMEM/2% stripped serum, and transfected with 5 µg/dish of the different c-myc mutant 
constructs. At the end of transfection cells were incubated for 24 hours in DMEM/5%FBS 
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+/- 90uM quinidine before preparing cell extracts for luciferase assay. Luciferase activity 
was measured in cell extracts containing 200 µg of protein.  
A. Luciferase activities in quinidine-treated cells (hatched bars) are expressed as percent of 
respective controls (solid bars) for each construct. Data shown on the bar graph are the mean 
luciferase activity +/- S.D. of at least n=3 experiments.  
∗  Significantly different from control values (p<0.05). 
 
B. Luciferase activity in the cells transfected with Del-1 was set to 100%. Luciferase 
activities in cells transfected with other construct are expressed relative to the Del-1. Cells 
transfected with promoterless construct (Luc) always had luciferase activity less then 0.01% 
of the activity in the control cells transfected with myc-luc construct. Data shown in the bar 
graph represent the mean  +/- S.D. of at least n=3 experiments. 
 
 86 
 3.3.  Quinidine does not affect activity of the cyclin D1 promoter 
To examine the specificity of the effects of quinidine on the c-myc promoter, the 
human cyclin D1 promoter linked to the luciferase reporter gene was used. MCF-7 cells were 
transiently transfected with cyclinD1-luc construct in a similar procedure as described for the 
myc-luc plasmids in the section 3.1. Transfection reactions were terminated by replacing the 
medium with the fresh DMEM/5%FBS  +/- 90 µM quinidine. Twenty-four hours later, 
luciferase activity in cell extracts was measured. As shown in Table 4A, quinidine did not 
cause significant changes in the activity of the cyclin D1 promoter. This is an important 
control for the specificity of quinidine's effects on the c-myc promoter. 
 
3.4.  Quinidine does not affect enzymatic activity of purified luciferase protein 
The reporter gene system allows one to measure the promoter activity of the gene of 
interest. In this system the promoter sequence is linked to the reporter gene coding sequence. 
As a result, any changes in the promoter activity would cause the corresponding changes in 
the levels of the reporter protein, e.g. luciferase. The changes in promoter activity of the gene 
of interest are measured indirectly by measuring enzymatic activity of the reporter protein. 
Therefore, it is important to demonstrate that changes in the activity of particular promoter in 
response to the drug treatment are not due to the direct effect of that drug on the enzymatic 
activity of the reporter protein. In order to show that quinidine has no effect on the activity of 
luciferase protein, the extracts of the control and quinidine-treated MCF-7 cells were used. 
One hundred pg of purified luciferase protein was added to both cell extracts and the 
luciferase activities in these samples were assayed in an identical manner as described for the 
myc-luciferase construct in section 3.1. As shown in Table 4B, quinidine had no effect on the 
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enzymatic activity of the purified luciferase protein. These results are important, because 
they demonstrate that any quinidine-induced changes in the luciferase activity in the extracts 
of cells transfected with the myc-luciferase construct (see Figure 14 and 16) are likely to be 
due to the corresponding changes in the activity of the c-myc promoter. 
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                    A.  Effect of quinidine on the cyclin D1 promoter activity 





Luciferase Activity (% of control) 
 
 
       Control 
 
100 
       Quinidine 
 
120 (+/- 15.3) 
 
 
          B.  Effect of quinidine on the enzymatic activity of purified luciferase 





Luciferase Activity (% of control) 
 
       Control 
 
100 
       Quinidine 
 
99 (+/- 1) 
 
 
Table 4. Effect of quinidine on the cyclin D1 promoter and purified luciferase activity. 
 
Confluent MCF-7 cells were sub-cultivated, transferred into PRF-DMEM/2% stripped 
serum, and transfected with 5µg/dish of the human cyclin D1-luciferase plasmid (A) or with 
transfection reagent alone (B). Transfected cells were incubated for 24 hours in 
DMEM/5%FBS medium +/- 90 µM quinidine before preparing cell extracts for the luciferase 
assay. 
A. Luciferase activity was measured in extracts containing 200 µg of protein. Luciferase 
activity in the quinidine-treated cell extracts is expressed as a percent of that in the control 
cells (100%). Data shown are the mean +/- S.D. of n = 4 experiments. 
B. 100 pg of the purified luciferase protein were added to the control and quinidine-treated 
cell extracts containing 200 µg of proteins before luciferase activity was measured. 
Luciferase activity in the quinidine-treated cell extracts is expressed as a percent of that in 
the control cells (100%). Data shown are the mean +/- S.D. of n = 3 experiments. 
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3.5.  The role of TGFβ1 control element and Sp1/Sp3 binding site of a QRR in the 
regulation of c-myc promoter by quinidine 
The results from the experiment 3.2 suggest that putative QRE is located within 168 bp 
region of the c-myc promoter. This region contains two important cis-elements: the TGFβ1 
control element (TCE) and GC-rich region from -60 to -37 that contains Sp1/Sp3 binding site 
(see Table 3). In the next series of experiments we tested the role of these elements in the 
regulation of c-myc promoter by quinidine. In general, the regulation of gene promoter by 
particular agent via a cis-element can be achieved by several mechanisms, some of which are 
listed here: 1) by changing the binding of trans-acting factors to the element, without altering 
their protein levels, 2) by changing the protein levels of trans-acting factors, 3) by binding 
directly to the cis-element, preventing further binding of trans-acting factors. 
Effects of quinidine on Sp1 and Sp3 protein levels in MCF-7 cells. The goal of this 
experiment was to test if quinidine alters the levels of Sp1 and Sp3 proteins. Confluent MCF-
7 cells were re-plated in 60 mm2 dishes in 5 ml DMEM-5 %FBS at the density of 1x106 
cells/dish and treated with 90 µM quinidine or H2O (vehicle). Cells were harvested 90 min 
later for Western blot analysis. Equal amounts of proteins (10 µg for Sp1 and 20 µg for Sp3 
gel) were loaded into each well of 7.5 % polyacrylamide gels. As shown in Figure 17, 
quinidine didn’t change the levels of either protein. The results indicate that suppression of c-
myc promoter by quinidine is not mediated by the changes in Sp1/Sp3 protein levels. This 
does not exclude the possibility of Sp1/Sp3 involvement in regulation of c-myc promoter by 
quinidine, since binding of these proteins to the GC-rich region of QRR but not their levels 
could be responsive to quinidine. Sp1 and Sp3 are ubiquitous transcription factors that are 
involved in regulation of a number of genes. Hence, changes in the levels of Sp1/Sp3 
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proteins will affect expression pattern of all those genes. The Sp1 transcription factor can 
regulate transcription by at least two mechanisms: 1) binding GC-rich sequence directly or 2) 
indirectly interacting with other transcription factors to alter gene transcription (Porter, W. et 
al., 1996). For example, Sp1 can form a complex with the ER, which then binds to DNA 
regions containing both Sp1 elements and ERE-half sits (Porter, W. et al., 1996; Wu-Peng, 
X. et al., 1992). Therefore, transactivating activity of Sp1 factor may be influenced by the 
presence of other responsive elements next to the GC-rich region. Sequence analysis of 
cyclin D1 promoter revealed a presence of two consecutive Sp1 binding sites between base 
pairs –113 and –102. This Sp1-binding region has also been shown to bind Egr-1 (early 
growth response protein-1) transcription factor. A dual interplay between Egr-1 and Sp1 
response elements has been described for a number of promoters (Khachigian, L. et al., 1995; 
Skerka, C. et al., 1995; Ebert, S. and Wong, D., 1995) including cyclin D1 promoter 
(Guillemot, L. et al, 2001). In this model Egr-1 displaces Sp1 at the overlapping motifs to 
activate transcription of its target genes (Khachigian, L. et al., 1995; Cui, M. et al., 1996) In 
my experiments quinidine had a minimal effect on cyclin D1 promoter activity, indicating 
that quinidine does not affect binding of Sp1 protein to the cyclin D1 promoter. The 
preferential regulation of Sp1/DNA interaction in c-myc but not cyclin D1 promoter by 
quinidine could be explained by the overlapping nature of Sp1/Egr sites of cyclin D1 
promoter. This issue can be resolved by examining the changes in Sp1/DNA interaction of c-





Figure 17. Quinidine does not change the levels of Sp1 and Sp3 proteins. 
 
Confluent MCF-7 cells were sub-cultivated in DMEM/5% FBS +/- 90 uM quinidine. Cells 
were harvested 90 min later and Sp1/Sp3 proteins levels after Western blot assay were 
determined by densitometry. The β-catenin signals were used as a loading control. The bar 
graph shows Sp1 (left panel) and Sp3 (right panel) proteins levels in control (solid bars) and 





The role of TCE in regulation of c-myc promoter by quinidine. Normal human mammary 
epithelial cells, MCF10A, respond to TGFβ1 treatment by rapid (within 2 hours) decrease in 
Myc protein levels and subsequent inhibition of cell growth. These effects are abolished in 
breast cancer cell lines and in MCF10A cells transformed with Ras/ErbB2 oncogenes (Chen, 
C. et al, 2001). Down-regulation of c-myc promoter activity through TCE has been reported 
to play a key role in TGFβ1 mediated growth inhibition in different cell lines (Pietenpol, J. et 
al, 1991; Chen, C. et al, 2001). In order to test the role of TCE in the regulation of c-myc 
promoter by quinidine, a series of experiments were performed to compare effects of 
quinidine and TGFβ1 on proliferation and Myc protein levels in different cell lines. 
MCF10A cells were re-plated from confluent T-75 flasks at the density of 6 x 105 
cells/60 mm2 (for Western blot) or 1 x 105 cells/35 mm2 (for cell count) tissue culture dishes 
in 5 or 3 ml MEGM medium, respectively. Cells were treated with: vehicle (4mM HCl, 
1mg/ml BSA - 1µl/ml of medium), 90 µM quinidine, 5ng/ml TGFβ1, 90 µm quinidine + 
5ng/ml TGFβ1. For Western blot assay, cells were harvested 24 hours later and equal 
amounts of proteins (60 or 70 µg) for each sample were separated on 10% polyacrylamide 
gels. For cell count assay, cells were harvested 72 hours later. As shown in Figure 18, 
quinidine had little effect on cell number and Myc protein levels, whereas TGFβ1 caused a 
significant reduction of both. Quinidine+TGFβ1 had additive effects on cell number and Myc 
levels, which indicates that these agents work through the different pathways. Also, 
quinidine, but not TGFβ1, inhibited growth of MDA-468, MDA-231, and MCF-7 breast 
cancer cells (Figure 19). MDA-468 cell line has a defective TGFβ1 pathway due to the lack 
of an important mediator of TGFβ1 signaling, Smad4 transcription factor (Chen, C. et al, 
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2001). Jointly, these results suggest that regulation of c-myc and subsequently cell growth by 
quinidine and TGFβ1 is mediated by different mechanisms in the described cell lines. 
In summary, the results presented in this section imply that suppression of c-myc 
promoter by quinidine is not mediated through TGFβ1 responsive element (TCE), due to the 
different responses of cells to TGFβ1 and quinidine (Figures 18 and 19). By eliminating TCE 
as a mediator of quinidine’s responses on c-myc promoter, the only other known regulatory 
element remaining within the proposed 168 bp QRE is the GC-rich region. This region has 
been shown to be essential for the transcription from the P1 promoter and can bind Sp1/Sp3 
transcription factors. Our results showed that quinidine does not affect the levels of these 
proteins (Figure 17). It is possible, that binding of these factors to the GC-rich region, but not 
their levels are altered by quinidine. 
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Figure 18. Quinidine and TGFβ1 have distinct effects on proliferation and Myc protein 
levels in MCF10A cells. 
Confluent MCF10A cells were sub-cultivated in MEGM +/- vehicle (4mM HCl, 1mg/ml 
BSA - 0.5 µl/ml of medium), 90 µM quinidine, 5ng/ml TGFβ1, 90 µm quinidine + 5ng/ml 
TGFβ1. Cells were harvested 24 (Western blot assay) and 72 (cell count assay) hours later.  
Myc protein levels were determined by densitometry and normalized to the β-catenin signals. 
The bar graph shows cell number (solid bars) and Myc protein levels (hatched bars) in 
control and treated cells. The data in the table represent mean +/- STDEV of n=2 






Figure 19. Quinidine and TGFβ1 have distinct effects on proliferation in normal 
(MCF10A) and tumor (MDA-231, MDA-468, MCF-7) breast epithelial cell lines. 
 
Confluent cultures of MDA-231, MDA-468, MCF-7, and MCF10A cells were sub-cultivated 
at the density of 1x105 (MDA-231, MDA-468, MCF10A) or 2x105 (MCF-7) per 35 mm2 
tissue culture dish in the presence of: C-vehicle (4mM HCl, 1mg/ml BSA - 0.5 µl/ml of 
medium), Q- 90 µM quinidine, T-5ng/ml TGFβ1, T+Q-90 µm quinidine + 5ng/ml TGFβ1. 
Cells were harvested 72 or 96 (for MCF-7) hours later and counted by hemocytometer. The 









4.   Quinidine Inhibits Growth and Induces More Differentiated phenotype in Human 
Breast Cancer Cells 
Another objective of this study was to determine the long-term effects of quinidine in 
breast cancer cells. c-myc plays an important role in cellular differentiation. It has been 
shown in many cells that down-regulation of c-myc accompanies terminal differentiation and 
permanent withdrawal from the cell cycle (Canelles, M. et al, 1997; Griep, A and Westphal, 
H., 1988; Holt, J. e al, 1988; Prochownik, E. et al, 1988). My results demonstrate that 
quinidine inhibits Myc protein and mRNA levels in human breast cancer cells, probably by 
regulating the activity of c-myc promoter. Therefore, we tested whether quinidine also 
induces differentiation in these cells. The effects of quinidine on Ki-67 antigen expression 
and accumulation of the cytoplasmic lipid droplets have been tested. 
 
 4.1.  Quinidine decreases the percentage of the MCF-7 cells expressing the Ki-67 
antigen 
Ki-67 is a nuclear protein found in cells that are actively engaged in the cell cycle (van 
Dierendonck, et al, 1989). The turnover rate of Ki-67 protein is less than 1 hour (Bruno and 
Darzynkeiwicz, 1992); therefore, its absence from cells is an indication that cells have exited 
the cell cycle and entered G0 or non-proliferative state that is associated with the cellular 
differentiation.  
To test the effects of quinidine on the expression of Ki-67 protein, MCF-7 cells were 
replica plated at the density of 2 x 105/35 mm2 tissue culture dish in 3 ml of DMEM/5%FBS 
medium +/- 90 µM quinidine. Twelve, 18, 24, 30, 48, and 72 hours later cells were fixed and 
stained for Ki-67 immunoreactivity as detailed in the Materials and Methods. Figure 20 
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shows a representative picture of the control and quinidine-treated MCF-7 cells after 
immunohistochemical staining of Ki-67 antigen (brown color) and counter-staining with 
Mayer's hematoxylin (blue color). Brown cells (Ki-67-positive) represent cell population in 
G1, S, G2, and M phase of the cell cycle. Blue cells (Ki-67-negative) represent the 
population of cells in G0 or non-proliferative state. The Ki-67-negative and positive cells 
were scored using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD).            
A minimum of 500 cells were counted per experimental condition. The results are shown in 
Figure 21. The quinidine-treated cells showed a significant increase in Ki-67 negative cells 
between 48 and 72 hours, compared to the control cells. These data suggest that quinidine-






Figure 20. Ki-67 immunohistochemical staining of MCF-7 cells. 
 
Control or 90 µM quinidine-treated MCF-7 cells were grown for 48 hours on the glass cover 
slips and assayed for Ki-67 immunoreactivity. Brown staining indicates Ki-67 positive or 








Figure 21. Increase in G0 cell population in MCF-7 cells treated with quinidine. 
 
Control or 90µM quinidine-treated MCF-7 cells were grown on the glass cover slips. At the 
indicated times, cells were stained for Ki-67 immunoreactivity, and Ki-67 positive and 
negative cells were counted. Between 200 and 700 cells were counted per experimental 
condition. The bars represent the percentage of Ki-67 negative cells in control (solid bars) 
and quinidine-treated cells (hatched bars). The data are mean +/- SEM of two to five 
experiments.  
∗  Significantly different from control values (p<0.05). 






4.2. Quinidine causes accumulation of cytoplasmic lipid droplets in MCF-7 cells. 
Lipid droplets are found in the cytoplasm of normal mammary epithelium (Jing, Y. et al, 
1996), and cytoplasmic lipid droplet accumulation occurs in a variety of differentiating cell 
systems. Induction of differentiation in human breast cancer cell lines by retinoic acid 
(Bacus. S. et al, 1990), the vitamin D analog, 1-α- hydroxyvitamin D5 (Mehta, R. et al, 
2000), and oncostatin M (Douglas, A. et al, 1998) is accompanied by the accumulation of 
cytoplasmic lipid droplets.  
To determine whether quinidine treatment induces the accumulation of cytoplasmic lipid 
droplets, the MCF-7 cells were replica plated at the density of 2 x 105/35 mm2 tissue culture 
dish in 3 ml of DMEM/5%FBS medium +/- 90 µM quinidine. Seventy-two, 96, and 120 
hours later cells were fixed and the Oil-Red O staining of the cells was performed as 
described in the Material and Methods. Figure 22 shows a representative picture of the 
control and quinidine-treated MCF-7 cells after the Oil-Red O staining and counter-staining 
with Mayer's hematoxylin to visualize the cytoplasmic lipid droplets (red color) and the cell 
nuclei (blue color), respectively. The Oil-Red O staining of the normal human mammary 
epithelial cells (HMEC), performed in an identical manner as for MCF-7 cells is also shown 
in the Figure 21. This picture demonstrates the morphological similarities between the 
quinidine-treated MCF-7 cells and untreated HMEC, implying that quinidine-treated tumor 
cells acquire a more differentiated phenotype. MCF-7 cells were scored as positive or 
negative for the presence of cytoplasmic lipid droplets using Image-Pro Plus software (Media 
Cybernetics, Silver Spring, MD). A minimum of 500 cells was counted per experimental 
condition. The results are shown in Figure 23. Quinidine caused a significant increase in lipid 
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droplets-positive MCF-7 cells at 70, 96, and 120 hours of treatment, compared to the control 
cells. 
In summary, the presented data show that quinidine treatment after 24 hours caused 
accumulation of MCF-7 cells in G0 state with the induction of the cytoplasmic lipid droplets 
after 48 hours. Since in general these changes are observed during cellular differentiation, we 








Figure 22. Oil Red O staining of the MCF-7 and HMEC. 
 
Control or 90 µM quinidine-treated cells were grown on glass cover slips. At the indicated 
times cells were stained with the Oil Red O stain (red dots in the cytoplasm) and 




Figure 23. Quinidine causes accumulation of cytoplasmic lipid droplets in the MCF-7 
cells. 
 
Control or 90 µM quinidine-treated MCF-7 cells were grown on the glass cover slips. At the 
indicated times cells were stained with Oil Red O to monitor accumulation of cytoplasmic 
lipid droplets. Lipid droplet positive and negative cells were counted. The bars represent the 
percentage of lipid droplet positive cells in control (solid bars) and quinidine-treated (hatched 
bars) cells. At least 500 cells were counted per experimental condition. Data shown in the 
histogram are the mean +/- S.D. of n = 3 experiments for 70 hours and results from single 
experiments for 96 and 120 hours. 
∗  Significantly different from control values (p<0.05).  
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 4.3.  Quinidine induces more differentiated phenotype in other breast cancer cell lines. 
The objective of this experiment was to test if quinidine induces more differentiated 
phenotype in other breast tumor cell lines. MCF-7, T47D, MDA-231, and MDA-435 cells 
were replica-plated at the densities of 0.8-3 x 105/35 mm2 tissue culture dish in 3 ml of 
DMEM/5%FBS  +/- 90 µM quinidine or 10 µM retinoic acid for 96 hours. The retinoic acid 
has been shown to induce differentiation in human breast cancer cells (Bacus. S. et al, 1990). 
Therefore, it was used as a positive control in this experiment. The Nile Red fluorescent 
stain, instead of the Oil Red O, was used to monitor lipid droplet formation in response to 
quinidine. The cells were counterstained with fluorescein-conjugated antibodies to phalloidin 
that bind actin filaments to assay for the changes in the actin cytoskeleton. The results are 
shown in Figure 24. Lipid droplet accumulation was weak or absent in the control cell lines 
and increased by retinoic acid and quinidine. Lipid droplets accumulation was more marked 
in all four cell lines treated with quinidine than with retinoic acid. 
These data demonstrate that induction of a more differentiated phenotype is a general 
response of human mammary tumor cells to quinidine. 
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Figure 24. Accumulation of cytoplasmic lipid droplets in mammary tumor cell lines in 
response to quinidine. 
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MCF-7, T47D, MDA-231, and MDA-435 cells were grown on glass cover slips in medium 
containing 0.01% ethanol (control), 10 µM retinoic acid, or 90 µM quinidine. After 96 hours, 
cells were fixed and stained with the Nile Red and fluorescein-phalloidin to identify lipid 
droplets (orange color) and actin filaments (green color), respectively. Images were obtained 
by confocal microscopy.  
 
Zhou, Q, et al, 2000. 
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4.4.  Quinidine inhibits proliferation in human breast tumor cell lines 
The data presented above suggest that quinidine induces differentiation in breast tumor 
cell lines. In general, the process of cellular differentiation is associated with an exit from the 
cell cycle and cessation of proliferation. Therefore, we next tested if quinidine also inhibits 
the growth in human mammary tumor cells. The effects of quinidine on cell growth was 
assayed by two different methods. In the first method breast cancer (MCF-7, MDA-231, 
MDA-435) and normal (HMEC, MCF10A) cells were replica-plated at the density of 1-1.5 
x105/35 mm2 dish in the DMEM/5% FBS (tumor cells) of MEGM (normal cells) medium +/- 
90 µM quinidine. Cell numbers were counted using a hemocytometer as described in the 
Materials and Methods. In the second method, cells were plated in a 96-well dishes at the 
following densities, depending upon the relative growth rates of the cell lines: HMEC (2000), 
MCF10A (1000), MCF-7 (1000), MDA-231 (500), T47D (1500). Cell growth was monitored 
using the MTS enzymatic assay as detailed in the Materials and Methods. The results are 
shown in Figure 25. Quinidine suppressed growth in all breast tumor cell lines, while having 
no effect in normal breast epithelial cells.  
The data presented above suggest that quinidine induces more differentiated phenotype 
and selectively inhibits cell growth in four different tumor, but not in normal breast epithelial 






Figure 25. Quinidine selectively inhibits growth in human breast tumor, but not in 
normal cell lines. 
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MCF-7, MDA-231, T47D, MCF-7ras tumor cells, and normal HMEC and MCF10A cells 
were replica-plated in 96-well plates for the MTS assay, or in 35 mm2 dishes for the cell 
count assay in control (open symbols) or 90 µM quinidine-containing medium (solid 
symbols). For the MTS assay (circles), results are the average of quadruplicates in one 
experiment. For the cells count assay (squares), the results represent the mean and SEM of 
three independent experiments for the MCF-7, T47D, and MDA-231 cell lines in duplicate 
dishes (MCF-7 and T47D), or single dishes (MDA-231) for each experiment. MCF-7ras and 
MCF10A data are the mean +/- range of two experiments performed in duplicate dishes. 
HMEC cell count data are from one experiment performed in single dishes. 
 
Zhou, Q., et al, 2000. 
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4.5.  c-myc antisense oligonucleotides mimic the effects of quinidine on lipid droplets 
formation in the MCF-7 cells 
The objective of this experiment was to test if suppression of Myc is sufficient to 
induce a more differentiated phenotype in breast tumor cells similar to quinidine. In fact, 
blocking of Myc activity using antisense oligonucleotides was shown to induce 
differentiation in several cell lines (Griep, A and Westphal, H., 1988; Holt, J. e al, 1988). 
MCF-7 cells were plated at the density of 2.2 x 105/35 mm2 tissue culture dish on glass cover 
slips in DMEM/5%FBS. Cells were allowed to attach to the cover slips and then the medium 
was exchanged to DMEM/2%FBS +/- 9 µM c-myc antisense oligonucleotides or +/- c-myc 
sense oligonucleotides (negative control). Ninety-six hours later cells were fixed and Oil Red 
O staining was performed as described in the Materials and Methods. The results are shown 
in Figure 26. MCF-7 cells treated with c-myc antisense oligonucleotides showed 
accumulation of cytoplasmic lipid droplets, whereas control and c-myc sense 
oligonucleotides-treated cells were predominantly lipid droplet-negative. These results 
suggest that specific down-regulation of the Myc activity is sufficient to induce lipid droplet 
formation in MCF-7 cells. Thus, it is conceivable, that inhibition of c-myc by quinidine is 
responsible for the morphological changes associated with more differentiated phenotype 
observed in quinidine-treated breast tumor cells. The presented results, as well as the data 
from other laboratories, suggest a critical role for Myc in regulation of cellular growth and 
differentiation in breast tumor cells. Therefore, it is important to understand the precise 
molecular mechanisms regulating c-myc gene expression by quinidine, which may reveal 




Figure 26. c-myc antisense oligonucleotides cause accumulation of cytoplasmic lipids in 
MCF-7 cells. 
 
MCF-7 cells were plated on glass cover slips and treated with nothing (control), 9 µM c-myc 
antisense oligonucleotides (mycAS), or 9 µM c-myc sense oligonucleotides (mycS). 96 hours 
later cells were stained with Oil Red O (red color) and counterstained with Mayer’s 
hematoxylin (blue color) to visualize cytoplasmic lipid droplets and cell nuclei, respectively. 







Previous studies indicate that quinidine causes G1/G0 cell cycle arrest and inhibition of 
proliferation in MCF-7 human breast cancer cell line (Woodfork, K. et al, 1995). The goal of 
studies presented here was to further understand the mechanisms underlying cell cycle arrest 
and inhibition of growth by quinidine. The regulation of c-myc gene by quinidine in human 
tumor and normal breast epithelial cell lines were studied. 
C-myc is one of the most common oncogene aberrations in breast cancers (Deming, S. et 
al, 1999; Garcia, I. et al, 1989; Escot, C. et al, 1986). The abnormal expression of c-myc was 
reported in 32% of breast cancers (Liu, E. et al, 1989), suggesting its important role in 
genesis and/or progression of breast cancer. Hence, understanding the mechanisms of c-myc 
gene regulation is important and may lead to the discovery of new targets for breast cancer 
therapy. In vivo studies with c-myc antisense oligonucleotides showed a significant increase 
in cancer-free survival of Eµ-transgenic mice compared to the animals treated with 
scrambled (negative control) oligonucleotieds (Akhtar, S. and Agrawal, S., 1997). In 
addition, mice with human melanoma xenografts showed a significant decrease in tumor size 
after systemic administration of c-myc antisense oligonucleotides (Leonetti, C. et al, 2001). 
My results demonstrate significant suppression of Myc by quinidine in four different human 
breast cancer cell lines growing in tissue culture (Figure 8). A large body of evidence 
established an important role of c-myc in cellular differentiation. Studies in different cell 
lines had shown that down-regulation of c-myc by antisense oligonucleotides or expression of 
dominant negative c-myc gene accompanies terminal differentiation and permanent 
withdrawal from the cell cycle (Ebinuma, H. et al, 1999; Canelles, M. et al, 1997; Griep, A. 
and Westphal, H., 1988; Holt, J. et al, 1988; Prochownik, E. et al, 1988). Conversely, 
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independent studies showed that ecotpic c-Myc expression from a transfected gene is 
sufficient to block the induction of differentiation in MEL, 3T3-L1 preadipocyte, F9, PC12 
neuronal, and U-937 monoblastic cell lines (Coppola, J.A., and Cole, M.D., 1986; 
Dmitrovsky, E. et al, 1986; Freytag, S., 1988; Larsson, L., et al, 1988; Maruyama, K. et al, 
1987, Onclercq, R. et al, 1989; Prochownik, E. and Kukowska, J., 1986). In consistence with 
these data, my results demonstrate that suppression of Myc by quinidine was associated with 
inhibition of growth and induction of a more differentiated (less malignant) phenotype in 
four different breast tumor cell lines (Figures 24 and 25). 
 The induction of differentiation (differentiation therapy) with a vitamin A derivative, all-
trans retinoic acid (ATRA) has been a major advance and become the first choice drug in the 
treatment of acute promyelocytic leukemia (APL) (Tobita, T. et al, 1997; McBurney, M. et 
al, 1993). The major principle behind the differentiation therapy is a pharmacologically 
induced conversion of poorly differentiated cancer cells back to the original differentiated or 
non-proliferative state. Since normal cells are already differentiated, ideally, they should not 
be affected by differentiation-inducing agents, leading to the less side effects compared to 
traditional cytotoxic chemotherapy. The successful treatment of APL with all-trans retinoic 
acid had led to attempts to apply the same principle for the treatment of other cancers. 
Unfortunately, differentiation therapy for solid cancers, such as breast cancer, generally, has 
been proven to be ineffective. Therefore, induction of a more differentiated phenotype in 
breast cancer cells by quinidine is a promising finding, suggesting a potential role for 
quinidine-like compounds in the therapy of breast cancer. In addition, differentiation-
inducing agents, such as retinoids, have been shown to be very effective in chemopreventive 
studies in breast cancer, cervical cancer, head and neck cancer, and lung cancer (Whelan, P., 
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1999). Chemoprevention is a relatively new branch of oncology, which aims to use chemical 
agents to reduce the incidence of malignant diseases in humans by suppressing 
carcinogenesis in premalignant lesions. In analogy to retinoids, quinidine-like compounds 
may also be effective as breast cancer chemopreventive agents. A better understanding of 
factors and mechanisms regulating differentiation (such as down-regulation of the c-myc), as 
well as their disruption in carcinogenesis would reveal new possibilities to design novel 
therapeutic approaches for chemopreventive and differentiation therapy of solid tumors. The 
results from my experiments indicate that quinidine suppresses the activity of c-myc 
promoter over the same range of concentrations that suppress levels of c-myc mRNA and 
protein (Figure 14). Myc protein, mRNA levels, and promoter activity were suppressed by 
68% (Figure 9), 78% (Figure 11), and 60-70% (Figure 16A) respectively by 90µM quinidine. 
The changes in c-myc mRNA and protein levels in response to quinidine may therefore be 
attributed to its effects on c-myc promoter. Furthermore, a 168 bp region (from –100 to +68 
in respect to P1) of the c-myc promoter was identified as a putative quinidine response region 
(QRR) (Figures 15 and 16). This region contains two important cis-elements: the TGF β1 
control element (TCE) and region from -60 to -37 that contains Sp1/Sp3 binding site 
(Nishikura, K., 1986, see Table 3). The first element is involved in inhibition of c-myc P1 
transcription initiation in response to TGF β1 (Pietenpol, J. et al, 1991), whereas the presence 
of intact second element is essential for P1 transcription (Nishikura, K., 1986). Quinidine had 
no effects on the levels of Sp1 or Sp3 proteins in MCF-7 cells (Figure 17). These results 
indicate that suppression of c-myc promoter by quinidine is not mediated by the changes in 
Sp1/Sp3 protein levels. However, it does not exclude the possibility of Sp1/Sp3 involvement 
in regulation of c-myc promoter by quinidine, since binding of these proteins to the GC-rich 
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region of QRR but not their levels could be responsive to quinidine. This issue can be 
resolved by electrophoretic mobility shift assay, that directly examines protein/DNA 
interactions in the promoter region of interest. In addition, my results suggest that regulation 
of c-myc and subsequently cell growth by quinidine and TGFβ1 is mediated by different 
mechanisms in breast cancer cell lines. It is also possible that suppression of the c-myc 
promoter in response to quinidine is mediated by the region within QRR that has not been 
described yet. To identify this potential new element, the fine mapping of QRR should be 
done by making small promoter deletions using polymerase chain reaction (PCR) and 
targeted single-stranded DNA primers. Determination of  QRE may lead to the identification 
of transcription factors that mediate suppression of c-myc promoter activity by quinidine. 
This in turn may reveal the signaling pathways that are involved in the regulation of c-myc 
gene and are targeted by quinidine.  
Alternative mechanism, by which quinidine can alter the expression of c-myc gene is via 
changing the acetylation of histones associated with c-myc promoter or transcription factors 
that bind to it. The chromatin structure and consequently the transcriptional activity of genes 
can be modulated by two families of proteins, via changes in the acetylation status of 
histones (Grunstein, M., 1997; Davie, J. and Chadee, D., 1998). Deacetylation of histones by 
histone deacetylases (HDACs) is, in general, associated with more condensed or 
transcriptionally inactive chromatin. In contrast, the hyperacetylation of histones by histone 
acetylases (HATs) has been linked to the transciptionally active chromatin (Kornberg, R. and 
Lorch, Y., 1999; Kouzarides T., 1999; Grunstein, M., 1997). A large body of evidence 
demonstrated, that agents that inhibit HDAC enzymatic activity, such as trichostatin A 
(TSA), superoylanilide hydroxamic acid (SAHA), trapoxin, and phenyl butyrate induce 
 116 
differentiation in a number of cell lines (Marks, P. et al, 2000; Medina, V. et al, 1997; 
Richon, V. et al, 1998; Sambucetti, L., 1999). The results from our laboratory showed that 
quinidine causes rapid degradation of HDAC-1, followed by histone hyperacetylation in 
MCF-7 cells (Zhou, Q. et al, 2000). Several studies, which used Raji cells (B cell line) stably 
transfected with episomal c-myc gene within self-replicating Epstein-Barr virus-derived 
vector, showed that mRNA transcription from both c-myc promoters, P1 and P2, is induced 
by two HDAC inhibitors, sodium butirate (Albert, T. et al, 2001) and tricostatin A (Madisen, 
L. et al, 1998). Therefore, suppression of c-myc promoter by quinidine is unlikely to be a 
result of quinidine-induced histone hyperacetylation. On the other hand, degradation of 
HDAC-1 by quinidine can alter the acetylation and subsequently DNA binding or 
transactivating activities of transcription factors that regulate c-myc promoter activity. In fact, 
the activities of several transcription factors have been reported to depend on their 
acetylation status (Gu, W. and Roeder, R., 1997; Munshi, N. et al, 1998; Waltzer, L. and 
Bienz M. et al, 1998). 
One of the major problems of current chemotherapeutic drugs for breast cancer treatment 
is their lack of selectivity for tumor tissue and associated with it toxicity in normal tissues. 
Importantly, quinidine had minimal effects on Myc levels or proliferation in normal breast 
epithelial cell lines (Figures 10 and 25). The difference in responses of tumor and normal 
cells to quinidine could be due to the lack of quinidine’s target in normal cells or its 
overexpression in tumor cells. For example, if changes in membrane potential in response to 
quinidine are involved and ultimately lead to the suppression of Myc, then the levels of 
expression of quinidine-sensitive potassium channels could be different in normal and cancer 
cells. In fact, the unique linear hyperpolarized current, which is inhibited by quinidine in 
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MCF-7 cells, is overexpressed in their Ha-ras transformed counterpart (Klimatcheva, E. and 
Wonderlin, W., 1999). The differential regulation of Myc in normal versus tumor cells could 
also be attributed to the differences in c-myc promoter sequence in these cells. 
In the studies presented here, as well as in the previous studies the maximal responses to 
quinidine were achieved at 90 µM concentration. The IC50 values of quinidine for growth 
inhibition, G0/G1 arrest, and suppression of Myc protein levels were 37.15 (Woodfork, K. 
dissertation, 1993), 24 +/-14 (Wang, S., 1998), and 27.3 +/- 13 µM (Figure 9), respectively. 
These values are above the therapeutic concentrations of quinidine as antiarrhythmic drug, 
which range from 2 to 6 µg/ml (5.3 to 15.8 µM). Additionally, 6 µg/ml (15.8 µM), 9 µg/ml 
(24 µM), and 14 µg/ml (37 µM) concentrations of quinidine caused side effects in 10, 30, 
and 50 % of patients, respectively (Goodman and Gilman’s, VII edition, 1985). The IC50 
values of quinidine for G0/G1 (24 µM) arrest and suppression of Myc (27µM) are close to 
the dose (24 µM) that causes toxic effects in only 30 % of patients. To minimize the toxic 
effects, the lower doses of quinidine can be used in combination with other differentiation-
inducing agents, such as retinoids. In fact, most of the chemotherapeutic regiments employ 
combination or polychemotherapy, consisting of the use of two or more compounds to 
achieve maximum kill of tumor cells with minimal toxicity.  
In summary, the studies presented here demonstrate a significant suppression of Myc 
levels by quinidine, which followed by inhibition of proliferation and induction of a more 
differentiated phenotype in four different human breast cancer cell lines growing in tissue 
culture. In contrast, quinidine had minimal effects on Myc protein levels and proliferation in 
normal breast epithelial cells. Differentiation-inducing agents, such as retinoids, have been 
successfully used for the treatment of acute promyelocytic leukemia, but not solid cancers. In 
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addition, retinoids, have been shown to be very effective in chemopreventive studies in 
breast cancer, cervical cancer, head and neck cancer, and lung cancer. Furthermore, in vitro 
and in vivo studies with c-myc antisense oligonucleotieds have shown promising results in 
treatment of several cancers. Therefore, suppression of Myc and induction of a more 
differentiated phenotype in breast cancer cells by quinidine is a promising finding, 
suggesting a potential role for quinidine-like compounds in chemopreventive and 
differentiation therapies of breast cancer. 
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